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THE CHEMOKINE RECEPTOR 4 (CXCR4) IN PRIMARY CUTANEOUS 
MELANOMA—CORRELATION WITH ESTABLISHED HISTOPATHOLOGIC 
PROGNOSTICATORS, BRAF STATUS AND EXPRESSION OF ITS LIGAND 
CXCL12 
BRENDON C. MITCHELL 
ABSTRACT 
Dysregulation of the chemokine receptor 4 (CXCR4) and its primary ligand 
CXCL12 (SDF-1, stromal cell-derived factor-1), has been implicated in the 
progression of melanoma and the mechanisms by which the CXCR4/CXCL12 
axis has been shown to activate cell cycle progression is via stimulation of the 
mitogen-activated protein kinase (MAPK) pathway. Given this, we sought to 
ascertain the potential cooperativity of CXCR4 with established histopathologic 
prognosticators including the BRAF status in primary cutaneous melanoma.  
In this IRB approved study, archived tissue samples with diagnosis of 
primary cutaneous melanoma were retrieved from the Skin Pathology Laboratory 
at BUSM, Boston, MA and a total of 107 cases identified as meeting criteria for 
inclusion. Protein expression of CXCR4 and CXCL12 were assessed using 
commercially available rabbit polyclonal antibodies (Ab2074 and, ab9797 
respectively, Abcam, Cambridge, MA, USA). CXCR4 gene expression (mRNA) 
was measured by semiquantitative RT-PCR with appropriate controls. For IHC, a 
semi-quantitative scoring (ranging from 0-3) was used and cases with a score of 
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≥2 (>10%) were considered positive. Molecular analysis for CXCR4 gene 
expression and BRAF exon 15 mutation status was performed using mRNA 
semi-quantitative RT-PCR and DNA Sanger sequencing respectively.  
Univariate analyses of CXCR4 mRNA expression revealed a statistically 
significant correlation between elevated CXCR4 expression (low ǍCt value) and 
presence of the BRAF mutation and absence of a host response (p=0.03 and 
p=0.0003 respectively). Univariate analyses revealed a significant correlation 
between elevated CXCR4 mRNA (low ǍCt value) and the following: presence of 
BRAF mutation and absence of a host response (p=0.03 and 0.0003 
respectively). CXCR4 mRNA was significantly higher among both AJCC stage 1 
and stage 3 compared to stage 2 (p=0.01). Compared with CXCR4 negative 
samples, univariate analyses of CXCR4 protein showed that the proportion of 
CXCR4 positives was significantly greater in melanomas with absence of mitoses 
(p<0.0001), ulceration (p=0.0008) and regression (p=0.02). Patients presenting 
at shallower stages (AJCC 1-2) exhibited a larger proportion of CXCR4 positives 
(76.9%, p<0.0001 and 69.0%, p=0.004), while those at deeper stages (AJCC 3-
4) exhibited a larger proportion of negatives (75.0%, p=0.002 and 66.7%, 
p=0.10). In a multivariable analysis, lower odds of CXCR4 protein expression 
were associated with AJCC stage-3 (OR=0.16, p=0.01), stage-4 (OR=0.17, 
p=0.04), and mitoses (OR=0.21, p=0.01).  
Lack of correlation between CXCR4 mRNA and protein expression 
suggests that further study is required for a more precise understanding of 
 vii 
mRNA-protein interaction for CXCR4 in order to identify factors contributing to 
the lack of concordance. CXCR4 protein appears to be associated with 
established prognosticators of good clinical outcome as its expression is less 
frequently observed in melanomas with mitoses, ulceration and depth >2 mm.  
The association between CXCR4 mRNA and a brisk host response suggests that 
it may serve as a biomarker for recruiting melanoma patients for immunotherapy. 
Higher CXCR4 mRNA in patients with a BRAF mutation suggests its utility as a 
putative therapeutic target. 
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INTRODUCTION 
 
1.1: Chemokine receptors and ligands—overview  
Members of the chemokine superfamily are small molecular weight 
signaling proteins (Payne & Cornelius 2002). Chemokines are classified into four 
groups based on the position of conserved cysteine residues—CC (2 adjacent N-
terminal cysteines) CXC (2 N-terminal cysteines separated by 1 amino acid), C 
(1 N-terminal cysteine), and CX3C (two N-terminal cysteines separated by 3 
amino acids)—and for each family of ligand there is a corresponding receptor 
(Payne & Cornelius 2002). In total, there are seventeen known chemokine 
receptors—CCR1-CCR11 and CXCR1-CXCR6 (Wu 2010). The class of CXC 
ligands stimulates the CXC receptors (CXCR), which are a class of receptors 
consisting of seven-transmembrane domains and a G-coupled protein 
(Torregrossa 2012).  
Chemokines and their receptors play an integral role in the immune 
system, directing leukocyte migration and regulating cellular proliferation (Balkwill 
2004b).  Chemokine receptor-ligand binding induces cytoskeletal rearrangement, 
which depending upon ligand concentration and quaternary structure can result 
in either firm adhesion or directional migration (Veldkamp 2008). Chemokines 
and their receptors—in particular CXCL12 and CXCR4—are believed to play a 
key role in cell migration and proliferation—two processes relevant in the 
progression and metastasis of cancer (Müller 2001; Sehgal 1998). 
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1.2 CXCR4 and CXCL12  
The chemokine receptor CXCR4 is coupled to a G-protein and consists of 
seven transmembrane alpha helices with a thirty-four amino acid extracellular N-
terminus (Wu 2010). Using X-ray crystallography it was determined that four 
domains of the receptor extend extracellularly and four domains extend 
intracellularly (Wu 2010). To date, known ligands for CXCR4 are CXCL12 
(stromal derived factor-1, SDF-1) and ubiquitin (Saini 2011). Ubiquitin does not 
bind the same site as CXCL12 and its effects are poorly understood (Saini 2011). 
The structure of CXCL12 has been visualized in nuclear magnetic resonance 
(NMR) studies, showing a 67 residue peptide consisting of an N-terminal strand 
and a core globular domain (Crump 1997). With the use of NMR spectroscopy, 
migration assays, and calcium measurements Crump et al. demonstrated in 1997 
that binding of CXCR4 and CXCL12 involves all extracellular domains of the 
receptor and both the core globular domain and N-terminus of the ligand 
resulting in a two site mechanism of binding for signaling transduction (Crump 
1997). A recent study further elucidated these two steps and demonstrated that 
electrostatic interactions of the N-loops, B-sheet, and 40-s loop of CXCL12 with 
the extracellular loops and N-terminus of CXCR4 (step 1) induces movement of 
the CXCR4 transmembrane domains (step 2) (Xu 2013). This transmembrane 
shift of the CXCR4 molecule provides access to a deep binding pocket allowing 
for interactions with the CXCL12 N-terminus, particularly Lysine-1 and Proline-2, 
resulting in signal transduction (Gupta 2001; Xu 2013).  
 Figure 1. Binding interaction 
A) Inactive state B) Step 1: 
extracellular loops and N-terminus of CXCR4
binding pocket and induces transmembrane movement for signal 
Of note, a recent in vitro
tyrosine residues located on the CXCR4 N
can be post-translationally sulfated to enhance ligand binding affinity
the important of all extracellular components of 
transduction (Ziarek 2013)
 
1.3 Pathways stimulated downstream of CXCR4  
Stimulation of CXCR4 by CXCL12 can activate four downstream signaling 
pathways leading to four distinct cellular responses 
phospholipase C pathway can be induced by CXCR4, which results in the 
release of intracellular calcium stores and c
Using human T-cells from the Jurkat cell line researchers showed that the 
3
of CXCR4 and CXCL12 
N-loops, B-sheet, and 40-s loop of CXCL12 interact 
 C) Step 2: CXCL12 N-terminus searches CXCR4 
transduction (Xu 2013)
 study of Chinese hamster ovarian cells showed that the 
-terminus at positions 7, 12, and 21 
the CXCR4 molecule to signal 
.  
 
(Drury 2011). The 
ellular migration (Kremer 2011)
 
with the 
 
, highlighting 
. 
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binding of CXCR4 to CXCL12 results in an increase of intracellular calcium and 
cellular migration in vitro (Kremer 2011). Another pathway that can be stimulated 
through CXCR4 is the RhoA pathway, which leads to an increase in the 
production of the collagenase membrane type-1 matrix metalloproteinase (MMT-
1 MMP) (Bartolomé 2004). Cross-talk between CXCR4 and MMT-1 MMP 
increases the invasiveness of malignant cells and enables them to migrate 
through membranes and extracellular matrices, thus enhancing metastatic 
potential (Bartolomé 2009). The PI3K/AKT pathway can also be activated by 
CXCR4 leading to cell survival (Luo 2013). In 2013, Luo et al. demonstrated that 
nasopharyngeal carcinoma-derived non-metastatic 6-10B and metastatic 5-8F 
cell lines displayed enhanced survival in the presence of CXCL12, while addition 
of PI3K/AKT pathway inhibitors blocked the survival promoting effects of CXCL12 
(Luo 2013). Lastly, the MAPK pathway may be stimulated resulting in cellular 
proliferation (Robledo 2001; Sun 2002; Alsayed 2007; Heinrich 2012). A study on 
the BLM melanoma cell line demonstrated that phosphorylation of the MAP 
kinases p44/42 (ERK1/2) and p38 (downstream of the Raf protein) upon in vitro 
CXCL12 administration, indicating enhanced MAPK pathway activation (Robledo 
2001). In summary, CXCR4 binding CXCL12 can induce migration, invasion, 
proliferation, and survival. These functions help delineate the contribution of the 
CXCR4/CXCL12 axis to the progression and metastasis of cancer. 
The pathways stimulated in response to CXCR4 binding CXCL12 are 
dependent upon the concentration and structure of CXCL12 (Veldkamp 2008; 
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Drury 2011). In 2008, in vitro studies of the human leukemic monocyte THP-1 
cell line demonstrated that the chemotactic response to CXCL12 was biphasic 
and occurred within a narrow concentration window (Veldkamp  2008). This 
same study showed that the monomeric form of CXCL12 stimulates cellular 
migration, whereas the dimeric form inhibits it (Veldkamp 2008). A 2011 study 
showed that in vitro administration of a monomeric CXCL12 slowly activated 
ERK1/2, whereas dimeric CXCL12 induced rapid ERK1/2 activation in human 
colorectal carcinoma cell lines, helping to explain the observed difference in 
response to monomeric and dimeric CXCL12 (Drury 2011). This study also 
elucidates how the extent of MAPK pathway stimulation, as influenced by 
CXCL12 concentration and quaternary structure, contributes to cellular 
phenotype (Drury 2011).  
The aforementioned studies have clarified the role of CXCR4 and CXCL12 
in controlling the cell cycle and chemotaxis. Most importantly, these findings have 
allowed researchers to identify this chemokine-receptor pair as a clinically 
relevant participant of cancer development and progression.  
 
1.4 Function of the CXCR4/CXCL12 axis 
Beginning as early as embryogenesis, CXCR4 and CXCL12 play a role in 
directing cellular migration in all mammals (Domanska 2013). In 1996 Nagasawa 
et al. demonstrated that loss of function of the CXCR4/CXCL12 axis results in 
defects in lymphopoeisis and bone marrow myelopoeisis (Nagasawa 1996). 
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Knockout studies of CXCR4 and CXCL12 in mice demonstrated a loss in stem 
cell migration and perinatal death due to failed embryonic development of the 
hematopoietic, renal, cardiovascular and nervous systems (Sierro et al., 2007; 
Takabatake 2009; Bonig & Papayannopoulou 2013; Mithal 2013. In addition to its 
contributions to embryonic development the CXCR4/CXCL12 axis is important to 
adult mammals as it directs immune responses, induces neovascularization and 
promotes cellular proliferation after injury (Fu 2013) (Liu 2013) (Bollag & Hill, 
2013). Varied expression of CXCL12 throughout the body allows for the 
establishment of CXCL12 gradients, which help to direct migration of CXCR4 
expressing cells (Loetscher et al., 2000). In 2000 Loetscher et al. demonstrated 
that constitutive CXCL12 expression at sites of inflammation results in the 
establishment of a CXCL12 gradient, which directs CXCR4 expressing 
phagocytic cells of the innate immune system (Loetscher 2000). A 2001 study 
showed that elevated CXCL12 expression was not limited to sites of 
inflammation, but was also be observed at the lymph nodes, lung, liver and bone 
marrow, whereas comparatively lower expression was demonstrated in the small 
intestine, kidney, skin, brain and skeletal muscle (Müller 2001). This pattern of 
expression is necessary for normal function of the immune system, directing 
lymphocyte trafficking (Stein & Nombela-Arrieta 2005). As will be discussed, 
anatomical sites of higher relative CXCL12 expression have been identified as 
common sites for metastatic development (Müller 2001).  
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1.5 CXCR4/CXCL12 in cancer  
To date, CXCR4 expression has been identified in 37 different primary 
tumors, in addition to many tumor metastases, of epithelial, mesenchymal, and 
hematopoietic origin (Balkwill 2004a). Expression of CXCR4 is not typically 
uniform throughout a neoplasm, but rather contained to a subpopulation of 
malignant cells (Balkwill 2004a). In 2001 Müller et al. performed in vitro migration 
and invasion assays confirming that murine CXCL12 enhances migration and 
invasion in human breast carcinoma MDA-MB-231 cells and showed that in vivo 
inhibition of the CXCR4/CXCL12 axis can block the development of metastasis, 
demonstrating for the first time the contribution of this axis to the metastatic 
cascade (Müller 2001). Briefly, Muller et al. co-injected breast carcinoma MDA-
MB-231 cells and a CXCR4 monoclonal antibody into severe combined 
immunodeficient mice and observed a 61-68% suppression of pulmonary 
metastasis formation compared to mice injected with MDA-MB-231 cells only 
(Müller 2001). This groundbreaking study set the template for future research of 
the roll of the CXCR4/CXCL12 axis in cancer progression and metastasis. 
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1.5.1 CXCR4/CXCL12 in hematopoietic malignancies 
The first study to implicate the CXCR4/CXCL12 axis in the progression of 
hematopoietic malignancies was published in 1999 by Möhle et al., who 
demonstrated a CXCR4 fluorescence intensity four times greater in B-
lymphocytes from patients with B-cell chronic lymphocytic leukemia (B-CLL) 
compared to normal B-lymphocytes and postulated that constitutive CXCL12 
expression in the bone marrow may promote the clinically observed infiltration 
and accumulation of lymphocytic blasts in the bone marrow of B-CLL patients 
(Möhle 1999). This was confirmed by in vitro migration assays performed in a 
conditioned medium of human bone marrow-derived stromal cells—high 
CXCL12—and showed that CXCL12 stimulated transendothelial migration to a 
greater extent in leukemic B-lymphocytes compared to normal B lymphocytes, 
implicating the CXCL12/CXCR4 axis as a contributor to the invasive capacity of 
malignant cells (Möhle 1999). In 2002 Ishibe et al. demonstrated a correlation 
between CXCR4 expression on B-cells from chronic lymphocytic leukemia 
patients and patient morbidity, indicating CXCR4 expression as a prognosticator 
for poor outcome in chronic lymphocytic leukemia (Ishibe 2002). Similar findings 
were published in a 2003 paper by Barretina et al. who used flow cytometry to 
quantify CXCR4 expression in B lymphocytes derived from B-CLL patients and 
identified a correlation between CXCR4 expression and lymphocyte counts, 
effectively associating CXCR4 expression with disease progression (Barretina 
2003). The same study also observed reduced CXCL12 levels in B-CLL patient 
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blood samples suggesting that low CXCL12 concentrations in blood may 
contribute to the propensity of B-CLL cells to migrate towards sites of greater 
CXCL12 expression for metastatic development (Barretina 2003). Möhle et al. 
followed up their 1999 findings with a study that demonstrated functional CXCR4 
protein expression on blast cells from patients with acute myeloid leukemia 
(AML) and acute lymphoblastic leukemia (ALL) by using flow cytometry and an in 
vitro CXCL12 induced calcium flux assay (Möhle 2000). This same study showed 
that CXCL12 induced transmembrane migration of AML and ALL cells (Möhle 
2000). The chemoattraction of CXCR4 expressing cells for CXCL12 allowed 
Möhle et al. to conclude that CXCR4 expression contributes to bone marrow 
compartmentalization—a site of high CXCL12 expression—often observed in 
ALL and AML patients (Möhle 2000). This same year a study by Crazzolara et al. 
identified a correlation between CXCR4 expression and extramedullary organ 
infiltration in patients with acute lymphoblastic leukemia, linking CXCR4 
expression to progression and metastasis (Crazzolara  2001). Seven years later, 
Spoo et al. showed that acute myeloid leukemia patients exhibiting low CXCR4 
expression, as measured by flow cytometry, displayed significantly longer 
survival compared to patients with medium and high expression, helping to 
classify CXCR4 protein expression as a prognosticator of poor patient outcome 
in acute myeloid leukemia (Spoo 2007). The same year, these findings were 
confirmed using immunohistochemistry to correlate CXCR4 expression to patient 
morbidity (Konoplev 2007). Yet another B-cell malignancy in which CXCR4 
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expression may contribute to metastatic development is follicular center 
lymphoma (Corcione 2000). Corcione et al. demonstrated CXCR4 protein 
upregulation in follicular center lymphoma B-cells as compared to normal 
germinal center B-cells by using flow cytometry (Corcione 2000). This same 
study compared in vitro CXCL12 induced migration of normal germinal center B-
cells and follicular center lymphoma B-cells and showed migration was enhanced 
in malignant B-cells, implicating the CXCR4/CXCL12 axis as a potential 
contributor to malignant cell migration away from the primary tumor site and the 
eventual development of metastasis (Corcione  2000). In 2003 Möller et al. 
demonstrated CXCR4 expression in multiple myeloma biopsies and revealed a 
potential role for the CXCR4/CXCL12 axis in directing multiple myeloma B-cells 
to compartmentalize in the bone marrow (Möller 2003). Briefly, the authors 
demonstrated that multiple myeloma cells and multiple myeloma cell lines 
express CXCR4 protein and exhibit a chemoattraction for CXCL12 through the 
use of flow cytometry, in vitro CXCL12 induced calcium influx measurements, 
and an in vitro migration assay (Möller 2003).  Möller et al. concluded that, much 
like in B-CLL, the high concentration of CXCL12 in the bone marrow causes 
compartmentalization of the multiple myeloma cells (Möller 2003). Interestingly, a 
2013 study by Bao et al. demonstrated that CXCR4 protein expression on 
multiple myeloma cells is correlated to longer patient survival, indicating CXCR4 
protein expression may be a prognosticator of good clinical outcome in multiple 
myeloma patients (Bao 2013).  
 11
In addition to B-cell malignancies, the CXCR4/CXCL12 axis has been 
implicated in the metastatic cascade of precursor myeloid cell and T-cell 
malignancies (Peled 2002; Weng 2003). In 2002 Peled et al. demonstrated that 
loss of function of CXCR4 in precursor myeloid cells from patients with chronic 
myelogenous leukemia (CML) allows for detachment and migration away from 
their primary tumor site in the bone marrow (Peled 2002). Briefly, flow cytometry 
and calcium flux assays performed on CML samples showed the presence of 
functional CXCR4 protein expression on pluripotent, immature CML cells (Peled 
2002). As mentioned previously, CXCL12 is constitutively expressed in the bone 
marrow and one would expect compartmentalization of CXCR4 expressing CML 
cells in the bone marrow; however, this is not observed (Peled 2002). Peled et al. 
attributed this unexpected behavior to a bcr-abl mutation common to CML cells, 
which inhibits stimulation of the CXCR4 pathway and allows for migration away 
from the bone marrow (Peled 2002). In contrast, normal blood cord cells lacking 
the bcr-abl mutation remain within the bone marrow until further maturation 
(Peled 2002). Peled et al. confirmed this hypothesis by demonstrating a weaker 
chemotactic response to CXCL12 and a weaker binding affinity for fibronectin in 
brc-abl mutated CML cells as compared to normal cord blood cells, indicating 
that the CML cells were more likely to detach from their surroundings, thus 
initiating the metastatic cascade (Peled 2002). Lastly, CXCR4 expression has 
been linked to T-cell malignancies as demonstrated by a study of TH1 and TH2 
lymphocyte subsets from patients with non-Hodgkin’s Lymphoma (Weng 2003). 
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Weng et al. showed that CXCR4 protein is preferentially expressed on malignant 
TH2 cells—a phenotypically aggressive subtype—compared to the “less” 
malignant TH1 cells and concluded that CXCR4 expression may contribute to the 
metastatic capacity of non-Hodgkin’s Lymphoma cells (Weng 2003).  
 
1.5.2 CXCR4/CXCL12 in other non-cutaneous malignancies 
Expression of CXCR4 has been studied in squamous cell carcinoma of 
the oral cavity, esophagus, cervix, and larynx (Uchida 2003; Gockel 2006; L. 
Zhang 2012; Huang 2013). Of these, CXCR4 and CXCL12 expression was first 
studied in oral squamous cell carcinoma (Uchida 2003). In 2003 Uchida et al. 
demonstrated enhanced expression of CXCR4 mRNA and protein in primary oral 
squamous cell carcinoma and metastases as compared to adjacent normal 
tissues; however, CXCR4 expression could not be correlated to patient prognosis 
or tumor size (Uchida 2003). In a 2007 follow-up study Uchida et al. noted a 
statistically significant decrease in the 5-year survival of oral squamous cell 
carcinoma patients exhibiting high CXCR4 and/or CXCL12 protein expression at 
primary tumor sites, linking the CXCR4/CXCL12 axis to poor patient outcome 
(Uchida 2007). In 2011 Uchida et al. demonstrated that metastatic development 
in nude mice injected with B88 oral squamous cell carcinoma cells could be 
inhibited by inoculation with the CXCR4 antagonist AMD3100, thus elucidating 
the potential therapeutic value of targeting the CXCR4/CXCL12 axis (Uchida 
2011).  
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In contrast to oral squamous cell carcinoma, studies of the 
CXCR4/CXCL12 axis in esophageal carcinoma have yielded conflicting results 
(Gockel 2006; Sasaki 2009; Wang 2009; Lu 2013). Briefly, in 2006 Gockel et al., 
using immunohistochemistry, showed CXCR4 protein expression in esophageal 
squamous cell carcinoma biopsies and noted an association between high 
expression and patient morbidity; although these findings did not achieve 
statistical significance (Gockel 2006). Following this, Sasaki et al. found that 
expression of CXCR4 protein did not correlate with clinicopathologic 
prognosticators nor patient survival, whereas Wang et al. demonstrated a 
correlation between expression and American Joint Committee on Cancer 
(AJCC) staging (Sasaki 2009; Wang 2009). Although these three studies fail to 
conclusively establish CXCR4 expression as a prognosticator for patient 
outcome, a recent study by Lu et al. highlighted the potential relevance of the 
CXCR4/CXCL12 axis in progression of esophageal squamous cell carcinoma (Lu 
2013). Briefly, Lu et al. demonstrated that CXCR4 expression at sites of 
esophageal squamous cell metastasis was significantly greater than primary 
tumor sites, implying that the upregulation of CXCR4 may occur with metastatic 
development (Lu 2013). The same study showed that high CXCR4 expressing 
cells, determined by flow cytometry, from the esophageal squamous cell 
carcinoma Ec109 cell line displayed enhanced migratory potential in vitro, 
providing further evidence that the CXCR4/CXCL12 axis may play a role in the 
metastatic cascade (Lu 2013).  
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Upregulation of CXCR4 and consequently stimulation of the 
CXCR4/CXCL12 axis has been implicated in the progression laryngeal 
squamous cell carcinoma (Tan 2008; Zheng 2011; Zhang 2012). In response to 
earlier findings implicating the CXCR4/CXCL12 axis in the progression of 
esophageal squamous cell carcinoma Tan et al. evaluated CXCR4 mRNA and 
protein expression, using RT-PCR and immunohistochemistry respectively, in 
laryngeal squamous cell carcinoma and demonstrated a correlation between 
expression and the development of metastasis (Tan 2008). A follow up study 
evaluated CXCR4 mRNA and protein expression and correlated expression to 
AJCC stage, presence of metastasis, and micro-vascularization, all of which 
identified CXCR4 expression as a prognosticator of poor patient outcome (Zheng 
2011). In 2012 Zhang et al. demonstrated that CXCR4 protein expression in 
laryngeal squamous cell carcinoma correlated with clinical stage and presence of 
metastasis, confirming the relevance of the CXCR4/CXCL12 axis in the 
progression and metastatic cascade of laryngeal squamous cell carcinoma 
(Zhang 2012). 
The role of the CXCR4/CXCL12 axis in cervical squamous cell carcinoma 
has been studied in three papers, all of which highlight its contribution to cancer 
progression and potential prognosticative value (Kodama 2007; Zhang 2007; 
Huang 2013). Briefly, in 2007 Kodoma et al. showed that CXCR4 protein 
expression, as determined by immunohistochemistry, correlated with advanced 
tumor staging, tumor size ≥4 mm, stromal invasion, absence of a brisk host 
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response, and lymph node metastasis, thus identifying CXCR4 expression as an 
indicator for poor patient outcome (Kodama 2007). Later that year Zhang et al. 
demonstrated CXCR4 protein expression in cervical squamous cell carcinoma 
Hela cells and showed Hela cell migration along a CXCL12 gradient in vitro, 
which implies that the CXCR4/CXCL12 axis may contribute to the migratory 
capacity of malignant cells, potentiating the metastatic cascade (Zhang 2007). In 
the same study, immunohistochemical analysis of cervical squamous cell 
carcinoma and corresponding lymph node biopsies revealed CXCR4 expression 
at the primary site and CXCL12 expression at the lymph node, confirming the 
conclusion of Zhang et al. that a CXCL12 gradient originating at the lymph node 
may attract primary tumor cells for metastasis (Zhang 2007). A more recent study 
confirms the prognostic value of CXCR4 by demonstrating a correlation between 
protein expression in primary cervical squamous cell carcinoma biopsies and 
histologic grade (Huang 2013).   
In addition to squamous cell carcinoma, the CXCR4/CXCL12 axis has 
been studied, although on a more limited basis, in adenocarcinoma of the 
pancreas, esophagus, cervix, and lung (Koshiba 2000; Gockel 2006; Yang 2007; 
Wagner 2009). Immunohistochemical analyses of pancreatic invasive ductal 
adenocarcinoma biopsies demonstrated CXCR4 protein expression in lesional 
tissue, but the absence of expression in adjacent normal tissue (Koshiba 2000). 
In the same study, although Koshiba et al. failed to correlate protein expression 
with clinicopathological features, in vitro chemotactic assays on pancreatic 
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cancer cell lines showed that CXCL12 enhances migration, favoring a role for the 
CXCR4/CXCL12 axis in the metastatic cascade of pancreatic adenocarcinoma 
(Koshiba 2000). In a 2009 study of pancreatic adenocarcinoma, high CXCR4 
expression, as established by semi-quantitative immunohistochemical scoring, 
correlated with the presence of lymph node metastasis and liver recurrence, 
indicating that CXCR4 expression may be a prognosticator for poor patient 
outcome (Maréchal 2009). Although limited to one study, and needing further 
investigation, CXCR4 protein expression in esophageal adenocarcinoma 
correlated with patient morbidity, but did not correlate with other established 
prognosticators (Gockel 2006). The following year Yang et al. determined that 
CXCR4 protein expression in cervical adenocarcinoma correlated with metastatic 
development and patient morbidity, indicating that expression may be a 
prognosticator of poor patient outcome (Yang 2007). A similar study on non-small 
cell lung adenocarcinoma demonstrated a correlation between CXCR4 protein 
expression and the following: presence of lymph node metastasis and shorter 
disease-free survival (Wagner 2009). These studies indicate that the 
CXCR4/CXCL12 axis may contribute to the progression of adenocarcinoma and 
serve as a valuable prognosticator for identifying advanced and/or phenotypically 
aggressive adenocarcinomas.  
 The chemokine receptor CXCR4 and its ligand CXCL12 have been 
studied in other non-cutaneous carcinomas as well. A study mentioned earlier by 
Müller et al. elucidated the relevance of CXCR4 and CXCL12 in breast 
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carcinoma (Müller 2001). Briefly, using RT-PCR and immunohistochemistry 
Müller et al. showed that CXCR4 mRNA and protein expression was absent in 
normal human mammary epithelial and ductal cells, but markedly upregulated in 
breast cancer cell lines and epithelial breast carcinoma metastasis biopsies 
(Müller 2001). In the same study, it was determined that the organs exhibiting the 
highest CXCL12 expression—lymph nodes, lungs, liver, and bone marrow—were 
also the most common sites of breast carcinoma metastasis, implicating the 
CXCR4/CXCL12 axis in the directional migration of malignant cells (Müller 2001). 
Two years later a study of the colon carcinoma cell line CT-26 demonstrated the 
importance of tumor microenvironment on CXCR4 expression (Zeelenberg 
2003). Zeelenberg et al. showed that CXCR4 protein expression in CT-26 cells 
was low in vitro, but significantly upregulated after injection and metastasis to 
murine spleen, liver, or lung (Zeelenberg 2003). In the same study, CXCR4-
deficient colonic carcinoma cells colonized the lung, but failed to proliferate at the 
same rate as CXCR4 positive colonic carcinoma cells (Zeelenberg 2003). 
Interestingly, Zeelenberg et al. showed that, in contrast to breast carcinoma, the 
CXCR4/CXCL12 axis appeared to contribute to malignant cell proliferation, but 
not migration in colon carcinoma (Zeelenberg 2003). These two early studies 
delineate the unique contribution of the CXCR4/CXCL12 axis in the progression 
of different malignancies (Müller 2001; Zeelenberg 2003). Despite these 
differences two recent studies demonstrated the prognostic value of CXCR4 
expression in both breast carcinoma and colon carcinoma (Xu 2013; Lv 2014). 
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Other carcinomas in which CXCR4 expression has been identified as a 
prognosticator of poor patient outcomes are clear cell renal carcinoma and non-
small cell lung carcinoma (Spano 2004; Wang 2012). In these studies 
immunohistochemical analyses demonstrated a correlation between CXCR4 
expression and shorter survival (Spano 2004; Wang 2012; Xu 2013; Lv 2014).  
Studies pertaining to the CXCR4/CXCL12 axis in thyroid carcinoma have 
elucidated its role in malignant progression as well as the potential cooperativity 
of this axis with mutated proteins downstream of its signaling cascade (Hwang 
2003; He 2010; Torregrossa 2012). In a study of anaplastic thyroid carcinoma 
cell lines, using flow cytometry and in vitro migration assays, researchers 
demonstrated CXCR4 protein expression and a chemotactic response to 
CXCL12 reiterating the potential contribution of the CXCR4/CXCL12 axis to the 
metastatic cascade (Hwang 2003). In a study of benign and malignant thyroid 
lesions, researchers noted that CXCR4 expression was greater in malignant 
lesions suggesting the importance of CXCR4 in malignant progression (He 
2010). In the same study, researchers compared CXCR4 expression in “more” 
malignant (poorly differentiated and medullary) versus “less” malignant (papillary 
and follicular) thyroid carcinomas and noted a significantly greater expression in 
the former (He 2010). More recently, in a study of papillary thyroid carcinoma, 
CXCR4 expression in primary biopsies correlated with tumoral infiltration, 
supporting the utility of CXCR4 expression as a prognosticator for poor patient 
outcome (Torregrossa 2012). In addition, this study noted a correlation between 
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CXCR4 expression and presence of a mutation in the MAPK BRAF protein 
(Torregrossa 2012).  
Studies of CXCR4 expression have elucidated the potential contribution of 
the CXCR4/CXCL12 axis in the progression of various sarcomas, but have been 
limited in number. In 2002 expression of CXCR4 was first identified on cell lines 
derived from rhabdomyosarcoma and it was demonstrated that in vitro 
administration of CXCL12 induced migration and membrane invasion, implying 
that dysregulation of the CXCR4/CXCL12 axis may potentiate the metastatic 
cascade (Libura 2002). Similarly, a 2010 study demonstrated CXCR4 protein 
expression in chondrosarcoma biopsies and showed that CXCL12 enhanced 
invasion in vitro (Sun 2010). This study also demonstrated that CXCR4 
antagonists and MAPK inhibitors negated the observed effects of CXCL12, 
highlighting the potential therapeutic value of targeting CXCR4 (Sun 2010). To 
date, the prognostic value of CXCR4 in rhabdomyosarcoma and 
chondrosarcoma has not been evaluated. A 2012 study using flow cytometry 
demonstrated CXCR4 expression in Ewing sarcoma biopsies and in vitro 
migration and proliferation assays with Ewing sarcoma cell lines showed that 
CXCL12 has a proliferative effect, but no effect on migratory, leading the authors 
to conclude that the CXCR4/CXCL12 axis may be relevant in the growth of this 
malignancy (Berghuis 2012). Of note, this study failed to correlate CXCR4 
expression with metastatic development, but identified a significant correlation 
with patient morbidity indicating that CXCR4 may be a predictive of poor patient 
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outcome (Berghuis 2012). The same year, a study demonstrated a similar 
prognostic value for CXCR4 in osteosarcoma by showing that the intensity of 
immunohistochemical staining for CXCR4 protein correlated with patient 
morbidity (Ma 2012).  
The CXCR4/CXCL12 axis has been implicated in a variety of cancers 
derived from the nervous system as well. A 2001 study demonstrated expression 
of CXCR4 protein on neuroblastoma cell lines and showed that in vitro 
administration of CXCL12 resulted in downregulation of CXCR4 (Geminder 
2001). A common site for neuroblastoma metastasis is the bone marrow 
(Geminder 2001). Given this, Geminder et al. hypothesized that high 
concentrations of CXCL12 in the bone marrow may induce CXCR4 
downregulation on malignant neuroblastoma cells causing compartmentalization 
within the bone marrow and resulting in metastatic development (Geminder 
2001). This was confirmed in a follow up study by Russell et al. who 
demonstrated that CXCR4 protein expression correlated with tumor staging and 
the presence of bone marrow metastasis, confirming the importance of the 
CXCR4/CXCL12 axis in disease progression and the potential prognostic utility 
of CXCR4 (Russell 2004). In two other tumors, astrocytoma and glioblastoma, 
researchers demonstrated CXCR4 mRNA expression using RT-PCR and 
showed that in vitro CXCL12 administration to rat astrocytes induced cellular 
proliferation (Barbero 2002). Although the findings of Barbero et al. revealed a 
potential contribution to tumor progression, to date the prognostic value of 
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CXCR4 expression in astrocytoma and glioblastoma has not been evaluated. 
Table 1. Chronologic historical overview of studies on CXCR4 in non-cutaneous 
malignancies  
REFERENCE STUDY DESIGN FINDINGS CONCLUSION 
Möhle et al. 
1999 
Samples studied: 
B-cell chronic 
lymphocytic 
leukemia and 
normal B-
lymphocytes 
Methods: Flow 
cytometry for 
CXCR4 protein 
and in vitro 
migration assay 
 
CXCR4 fluorescence 
intensity four times 
greater in B-lymphocytes 
from patients with B-cell 
chronic lymphocytic 
leukemia, as compared to 
normal B-lymphocytes; 
CXCL12 stimulates 
transendothelial migration 
to a greater extent in 
leukemic B-lymphocytes 
compared to normal B 
lymphocytes 
The CXCR4/CXCL12 axis 
may enhance the invasive 
capacity of chronic 
lymphocytic leukemia B-
lymphocytes contributing to 
disease progression and 
metastatic development. 
Möhle et al. 
2000 
Samples 
studied: Acute 
myeloid leukemia 
and acute 
lymphoblastic 
leukemia 
Methods: Flow 
cytometry for 
CXCR4 protein, in 
vitro calcium flux 
assay and 
transmembrane 
migration assay 
CXCR4 protein expressed 
on acute myeloid 
leukemia blasts and acute 
lymphoblastic leukemia 
blasts; CXCL12 induces 
intracellular calcium influx 
and transmembrane 
migration 
The CXCR4/CXCL12 axis 
may contribute to bone 
marrow accumulation of 
acute myeloid leukemia 
blasts and acute 
lymphoblastic leukemia 
blasts. 
Corcione et al. 
2000 
Samples 
studied: Follicular 
center lymphoma 
B-cells and 
normal germinal 
center B-cells 
Methods: Flow 
cytometry for 
CXCR4 and in 
vitro migration 
assay 
CXCR4 protein 
upregulation in follicular 
center lymphoma B-cells 
as compared to normal 
germinal center B-cells; 
CXCL12 induces greater 
migration of malignant B-
cells as compared to 
normal germinal center B-
cells 
The CXCR4/CXCL12 axis 
may contribute to the 
metastatic cascade by 
directing malignant cell 
migration along a CXCL12 
concentration gradient. 
Geminder et 
al. 2001 
Sample studied: 
Neuroblastoma 
cell lines 
Methods: Flow 
CXCL12 induces 
downregulation of CXCR4 
High concentrations of 
CXCL12 in the bone 
marrow may induce CXCR4 
downregulation on 
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cytometry for 
CXCR4 and in 
vitro migration 
assay 
malignant neuroblastoma 
cells causing 
compartmentalization within 
the bone marrow and 
metastatic development 
Koshiba et al. 
2000 
Samples 
studied: 
Pancreatic 
invasive ductal 
adenocarcinoma 
and cell lines 
Methods: IHC for 
CXCR4 protein 
and in vitro 
migration assay 
CXCR4 protein 
expression in lesional 
tissue, but absent in 
adjacent normal tissue; 
CXCR4 protein 
expression does not 
correlate with 
clinicopathological 
features; CXCL12 
enhances migration 
The CXCR4/CXCL12 axis 
may contribute to 
progression and metastasis 
of pancreatic invasive 
ductal adenocarcinoma. 
Crazzolara et 
al. 2001 
Sample studied: 
Acute 
lymphoblastic 
leukemia 
Method: Flow 
cytometry for 
CXCR4 protein 
CXCR4 protein 
expression correlates with 
extramedullary organ 
infiltration 
CXCR4 protein expression 
may be of utility as a 
prognosticator for poor 
outcome in patients with 
acute lymphoblastic 
leukemia. 
Müller et al. 
2001 
Sample studied: 
Breast carcinoma 
metastasis and 
cell line 
Method: RT-PCR 
for CXCR4 mRNA 
and IHC for 
CXCR4 protein 
CXCR4 mRNA and 
protein expression absent 
in normal human 
mammary epithelial and 
ductal cells, but markedly 
upregulated in breast 
carcinoma cell lines and 
epithelial breast 
carcinoma metastasis; 
CXCL12 expression 
greatest at common sites 
of breast carcinoma 
metastasis. 
The CXCR4/CXCL12 axis 
may contribute to 
progression and perhaps 
be involved in directing 
sites at which metastasis of 
breast carcinoma may 
occur. 
Libura et al. 
2002 
Sample studied: 
Rhabdomyosarco
ma cell lines  
Methods: Flow 
cytometry for 
CXCR4 protein, in 
vitro migration and 
transmembrane 
invasion assays 
 
CXCR4 protein 
expression is present; 
CXCL12 induces 
migration and membrane 
invasion 
The CXCR4/CXCL12 axis 
may potentiate the 
metastatic cascade in 
rhabdomyosarcoma. 
Ishibe et al. Sample studied: CXCR4 protein CXCR4 protein expression 
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2002 B-cell chronic 
lymphocytic 
leukemia  
Method: Flow 
cytometry for 
CXCR4 protein 
 
expression correlates with 
patient morbidity 
may be of utility as a 
prognosticator for poor 
outcome in patients with B-
cell chronic lymphocytic 
leukemia. 
Peled et al. 
2002 
Samples 
studied: Chronic 
myelogenous 
leukemia and 
normal cord blood 
cells 
Methods: Flow 
cytometry for 
CXCR4 protein, in 
vitro calcium flux 
assay, migration 
assay, and cell 
adhesion assay 
CXCR4 protein 
expression present on 
chronic myelogenous 
leukemia cells; CXCL12 
induces intracellular 
calcium flux and migration 
of normal cord blood cells 
but not chronic 
myelogenous leukemia 
cells  
 
Inhibition of the 
CXCR4/CXCL12 axis by 
the presence of a bcr-abl 
mutation may initiate 
chronic myelogenous 
leukemia cell migration 
away from the bone 
marrow, potentiating the 
metastatic cascade. 
Barbero et al. 
2002 
Sample studied: 
Astrocytoma, 
glioblastoma and 
rat astrocytes 
Methods: RT-
PCR for CXCR4 
mRNA and in vitro 
proliferation assay 
 
CXCR4 mRNA 
expression is present; 
CXCL12 induces 
proliferation of rat 
astrocytes. 
The CXCR4/CXCL12 axis 
may contribute to the 
growth and development of 
astrocytoma and 
glioblastoma. 
Barretina et al. 
2003 
Sample studied: 
Chronic 
lymphocytic 
leukemia B-
lymphocytes and 
patient plasma 
samples 
Methods: Flow 
cytometry for 
CXCR4 and 
CXCL12 protein 
CXCR4 protein 
expression correlates with 
lymphocyte counts; 
CXCL12 expression 
significantly lower in B-
cell chronic lymphocytic 
leukemia patients as 
compared to disease free 
patients 
CXCR4 and CXCL12 
protein expression may be 
of utility as a prognosticator 
for poor outcome in patients 
with B-cell chronic 
lymphocytic leukemia. The 
CXCR4/CXCL12 axis may 
contribute to the metastatic 
cascade by directing 
malignant cell migration 
along a CXCL12 
concentration gradient. 
Möller et al. 
2003 
Samples 
studied: Multiple 
myeloma cell lines 
and multiple 
myeloma 
CXCR4 protein 
expression present on 
multiple myeloma cell 
lines and patient biopsies; 
CXCL12 induces calcium 
The CXCR4/CXCL12 axis 
may be implicated in bone 
marrow 
compartmentalization of 
multiple myeloma cells 
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Methods: Flow 
cytometry for 
CXCR4, in vitro 
calcium influx 
assay and 
migration assay 
influx and migration of 
multiple myeloma cells 
resulting from high CXCL12 
concentrations in the bone 
marrow. 
Weng et al. 
2003 
Sample studied: 
Non-Hodgkin’s 
lymphoma 
Method: Flow 
cytometry for 
CXCR4 protein 
CXCR4 protein 
expression greater on the 
more malignant TH2 cells 
as compared to TH1 cells 
CXCR4 expression may 
contribute to the metastatic 
capacity of these of non-
Hodgkin’s lymphoma cells 
and is associated with a 
more malignant phenotype. 
Uchida et al. 
2003 
Samples 
studied: Oral 
squamous cell 
carcinoma and 
metastasis 
Methods: RT-
PCR for CXCR4 
mRNA and IHC 
for CXCR4 protein 
Enhanced expression of 
CXCR4 mRNA and 
protein in oral squamous 
cell carcinoma and 
metastases as compared 
to adjacent normal 
tissues; CXCR4 
expression could not be 
correlated to patient 
prognosis or tumor size 
The CXCR4/CXCL12 axis 
may be relevant in the 
development and 
progression of oral 
squamous cell carcinoma. 
Zeelenberg et 
al. 2003 
Sample studied: 
CT-26 colon 
carcinoma cell line 
Methods: Flow 
cytometry for 
CXCR4 and 
murine injection 
CXCR4 protein 
expression in CT-26 cells 
low in vitro, but 
upregulated after injection 
and metastasis to murine 
spleen, liver, or lung; 
CXCR4-deficient CT-26 
cells colonize the lung, 
but fail to proliferate at the 
same rate as CXCR4 
positive CT-26 cells 
The CXCR4/CXCL12 axis 
may be relevant in the 
growth of colon carcinoma. 
CXCR4 expression may be 
influenced by tumor 
microenvironment. 
Hwang et al. 
2003 
Samples 
studied: Thyroid 
carcinoma cell 
lines 
Methods: Flow 
cytometry for 
CXCR4 protein 
and in vitro 
migration assay 
CXCR4 protein 
expression present in cell 
lines; CXCL12 induces 
migration of cell lines 
The CXCR4/CXCL12 axis 
may direct malignant cell 
migration, contributing to 
the metastatic cascade of 
thyroid carcinoma. 
Spano et al. 
2004 
Sample studied: 
Non-small cell 
lung carcinoma 
Method: IHC for 
CXCR4 protein 
expression correlates with 
patient morbidity 
CXCR4 protein expression 
may be of utility as a 
prognosticator for poor 
outcome in patients with 
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CXCR4 protein non-small cell lung 
carcinoma. 
Russell et al. 
2004 
Sample studied: 
Neuroblastoma 
Method: IHC for 
CXCR4 protein 
CXCR4 protein 
expression correlates with 
tumor staging and 
presence of bone marrow 
metastasis 
The CXCR4/CXCL12 may 
contribute to the metastatic 
cascade, particularly 
metastasis at the bone 
marrow of neuroblastoma 
patients. CXCR4 protein 
expression may be of utility 
as a prognosticator for poor 
outcome in patients with 
neuroblastoma.  
Gockel et al. 
2006 
Samples 
studied: 
Esophageal 
squamous cell 
carcinoma and 
esophageal 
adenocarcinoma 
Method: IHC for 
CXCR4 protein 
No significant association 
between CXCR4 protein 
expression and patient 
morbidity in esophageal 
squamous cell carcinoma; 
CXCR4 protein 
expression correlates with 
risk of morbidity in 
esophageal 
adenocarcinoma 
CXCR4 protein expression 
may be of utility as a 
prognosticator for poor 
outcome in patients with 
esophageal squamous cell 
carcinoma or esophageal 
adenocarcinoma. 
Yang et al. 
2007 
Sample studied: 
Cervical 
adenocarcinoma 
Method: IHC for 
CXCR4 protein 
CXCR4 protein 
expression correlates with 
metastatic development 
and patient morbidity 
CXCR4 protein expression 
may be of utility as a 
prognosticator for poor 
outcome in patients with 
cervical adenocarcinoma. 
Uchida et al. 
2007 
Sample studied: 
Oral squamous 
cell carcinoma 
Method: IHC for 
CXCR4 protein 
CXCR4 and CXCL12 
protein expressions 
correlate to patient 
morbidity 
CXCR4 and CXCL12 
protein expressions may be 
of utility as a prognosticator 
for poor outcome in patients 
with oral squamous cell 
carcinoma. 
Spoo et al. 
2007 
Sample studied: 
Acute myeloid 
leukemia 
Method: Flow 
cytometry for 
CXCR4 protein 
Patients with low CXCR4 
expression displayed 
significantly longer 
survival compared to 
patients with medium and 
high expression 
CXCR4 protein expression 
may be of utility as a 
prognosticator for poor 
outcome in patients with 
acute myeloid leukemia. 
Konoplev et 
al. 2007 
Sample studied: 
Acute myeloid 
leukemia 
Method: IHC for 
CXCR4 protein 
CXCR4 protein 
expression correlates with 
patient morbidity 
CXCR4 protein expression 
may be of utility as a 
prognosticator for poor 
outcome in patients with 
acute myeloid leukemia. 
Kodama et al. Sample studied: CXCR4 protein CXCR4 protein expression 
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2007 Cervical 
squamous cell 
carcinoma 
Method: IHC for 
CXCR4 protein 
expression correlates with 
the following: tumor 
staging, tumor size ≥4 
mm, stromal invasion, 
absence of a brisk host 
response, and presence 
lymph node metastasis 
may be of utility as a 
prognosticator for poor 
outcome in patients with 
cervical squamous cell 
carcinoma. 
Zhang et al. 
2007 
Samples 
studied: Cervical 
squamous cell 
carcinoma and 
Hela squamous 
cell carcinoma cell 
line 
Methods: IHC for 
CXCR4 and 
CXCL12 protein, 
flow cytometry for 
CXCR4 protein 
and in vitro 
migration assay 
CXCR4 protein 
expression present in 
cervical squamous cell 
carcinoma and CXCL12 
protein expression 
present in corresponding 
lymph nodes; Hela cells 
express CXCR4 protein 
and migrate along a 
CXCL12 gradient 
The CXCR4/CXCL12 axis 
may contribute to the 
metastatic cascade of 
cervical squamous cell 
carcinoma. 
Tan et al. 
2008 
Sample studied: 
Laryngeal 
squamous cell 
carcinoma 
Methods: RT-
PCR for CXCR4 
mRNA and IHC 
for CXCR4 protein 
CXCR4 mRNA and 
protein correlates to the 
development of 
metastasis 
CXCR4 mRNA and protein 
expressions may be of 
utility as a prognosticator 
for poor outcome in patients 
with laryngeal squamous 
cell carcinoma. 
Maréchal et al. 
2009 
Sample studied: 
Pancreatic 
adenocarcinoma 
Method: IHC for 
CXCR4 protein 
CXCR4 protein 
expression correlates with 
the presence of lymph 
node metastasis and liver 
recurrence 
CXCR4 protein expression 
may be of utility as a 
prognosticator for poor 
outcome in patients with 
pancreatic 
adenocarcinoma. 
Sasaki et al. 
2009 
Sample studied: 
Esophageal 
squamous cell 
carcinoma 
Method: IHC for 
CXCR4 protein 
CXCR4 protein 
expression does not 
correlate with patient 
morbidity or established 
histopathologic 
prognosticators. 
CXCR4 protein expression 
does not appear to be of 
utility as a prognosticator 
for poor outcome in patients 
with esophageal squamous 
cell carcinoma. 
Wang et al. 
2009 
Sample studied: 
Esophageal 
squamous cell 
carcinoma 
Method: IHC for 
CXCR4 protein 
expression correlates with 
tumor staging. 
The CXCR4/CXCL12 axis 
may be relevant in the 
progression of esophageal 
squamous cell carcinoma. 
CXCR4 protein expression 
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CXCR4 protein may be of utility as a 
prognosticator for poor 
outcome in patients with 
esophageal squamous cell 
carcinoma. 
Wagner et al. 
2009 
Sample studied: 
Non-small cell 
lung 
adenocarcinoma 
Method: IHC for 
CXCR4 protein 
CXCR4 protein 
expression correlates with 
metastatic development 
and patient morbidity. 
CXCR4 protein expression 
may be of utility as a 
prognosticator for poor 
outcome in patients with 
non-small cell lung 
adenocarcinoma. 
He et al. 2010 Samples 
studied: Benign 
and malignant 
thyroid lesions 
Method: IHC for 
CXCR4 protein 
CXCR4 protein 
expression is upregulated 
in malignant lesions as 
compared to benign 
lesions; CXCR4 protein 
expression is greater in 
“more” malignant (poorly 
differentiated and 
medullary) than “less” 
malignant (papillary and 
follicular) thyroid 
carcinomas 
The CXCR4/CXCL12 axis 
may be relevant to the 
development of a malignant 
phenotype in of thyroid 
lesions. 
Sun et al. 
2010 
Sample studied: 
Chondrosarcoma 
Methods: Flow 
cytometry for 
CXCR4 protein 
and in vitro 
migration assay 
CXCR4 protein 
expression is present; 
CXCL12 induces 
migration; CXCL12 
migratory effects can be 
abrogated with CXCR4 
antagonists and MAPK 
inhibitors. 
The CXCR4/CXCL12 axis 
may be relevant to the 
metastatic cascade of 
chondrosarcoma. The 
CXCR4/CXCL12 may be a 
viable target for treatment 
of chondrosarcoma. 
Uchida et al. 
2011 
Sample studied: 
B88 oral 
squamous cell 
carcinoma cell line 
Method: murine 
injection 
Abrogation of metastatic 
development when co-
injection with the CXCR4 
antagonist AMD3100 
The CXCR4/CXCL12 may 
be a viable target for 
treatment of oral squamous 
cell carcinoma. 
Zheng et al. 
2011 
Sample studied: 
Laryngeal 
squamous cell 
carcinoma 
Methods: RT-
PCR for CXCR4 
mRNA and IHC 
for CXCR4 protein 
CXCR4 mRNA and 
protein correlates with the 
following: tumor stage, 
presence of metastasis, 
and micro-vascularization 
CXCR4 mRNA and protein 
expressions may be of 
utility as a prognosticator 
for poor outcome in patients 
with laryngeal squamous 
cell carcinoma. 
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Zhang et al. 
2012 
Sample studied: 
Laryngeal 
squamous cell 
carcinoma 
Method: IHC for 
CXCR4 protein 
CXCR4 protein 
expression correlates with 
clinical stage and 
presence of metastasis. 
CXCR4 protein expression 
may be of utility as a 
prognosticator for poor 
outcome in patients with 
laryngeal squamous cell 
carcinoma. 
Wang et al. 
2012 
Sample studied: 
Clear cell renal 
carcinoma 
Method: IHC for 
CXCR4 protein 
CXCR4 protein 
expression correlates with 
patient morbidity 
CXCR4 protein expression 
may be of utility as a 
prognosticator for poor 
outcome in patients with 
clear cell renal carcinoma. 
Torregrossa et 
al. 2012 
Sample studied: 
Papillary thyroid 
carcinoma 
Method: IHC for 
CXCR4 protein 
CXCR4 protein 
expression correlates with 
tumoral infiltration and 
presence of a BRAF 
mutation 
CXCR4 protein expression 
may be of utility as a 
prognosticator for poor 
outcome in patients with 
papillary thyroid carcinoma. 
Berghuis et al. 
2012 
Samples 
studied: Ewing 
carcinoma cell 
lines 
Methods: Flow 
cytometry for 
CXCR4 protein, in 
vitro migration 
assay and 
proliferation assay 
CXCR4 protein 
expression is present; 
CXCL12 induces cell 
proliferation but not 
migration; CXCR4 protein 
expression correlates with 
patient morbidity 
The CXCR4/CXCL12 axis 
may be relevant in the 
growth and development of 
Ewing sarcoma. CXCR4 
protein expression may be 
of utility as a prognosticator 
for poor outcome in patients 
with Ewing sarcoma. 
Ma et al. 2012 Sample studied: 
Osteosarcoma 
Method: IHC for 
CXCR4 protein 
CXCR4 protein 
expression correlates with 
patient morbidity 
CXCR4 protein expression 
may be of utility as a 
prognosticator for poor 
outcome in patients with 
osteosarcoma. 
Lu et al. 2013 Samples 
studied: 
Esophageal 
squamous cell 
carcinoma and 
metastasis, Ec109 
esophageal 
squamous cell 
carcinoma cell line 
Methods: IHC for 
CXCR4 protein, 
flow cytometry for 
CXCR4 protein 
and in vitro 
migration assay 
CXCR4 protein 
expression greater in 
metastasis than primary 
oral squamous cell 
carcinoma; higher CXCR4 
protein expression 
correlates with enhanced 
migratory response to 
CXCL12 
The CXCR4/CXCL12 axis 
may be relevant in the 
progression and metastasis 
of esophageal squamous 
cell carcinoma. 
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IHC=immunohistochemistry 
 
 
 
1.5.3 CXCR4/CXCL12 in cutaneous non-melanoma malignancies 
Both CXCR4 and its ligand CXCL12 appear to be involved in the 
progression and metastasis of cutaneous malignancies. In a study of the 
precancerous lesion actinic keratosis, basal cell carcinoma and cutaneous 
squamous cell carcinoma researchers demonstrated the presence of CXCR4 
protein; however, compared to normal skin, expression appeared to be 
downregulated in actinic keratosis and basal cell carcinoma, while cutaneous 
squamous cell carcinoma exhibited upregulated expression (Basile 2008). Given 
the limited metastatic potential of basal cell carcinoma compared to squamous 
cell carcinoma, this study supports the notion that CXCR4 expression is 
Bao et al. 
2013 
Sample studied: 
Multiple myeloma 
Method: IHC for 
CXCR4 protein 
CXCR4 protein 
expression correlates with 
patient survival 
CXCR4 protein expression 
may be of utility as a 
prognosticator for good 
outcome in patients with 
multiple myeloma. 
Huang et al. 
2013 
Sample studied: 
Cervical 
squamous cell 
carcinoma 
Method: IHC for 
CXCR4 protein 
CXCR4 protein 
expression correlates with 
tumor histologic grade. 
CXCR4 protein expression 
may be of utility as a 
prognosticator for poor 
outcome in patients with 
cervical squamous cell 
carcinoma. 
Xu et al. 2013 Sample studied: 
Breast carcinoma 
Method: IHC for 
CXCR4 protein 
CXCR4 protein 
expression correlates with 
patient morbidity 
CXCR4 protein expression 
may be of utility as a 
prognosticator for poor 
outcome in patients with 
breast carcinoma. 
Lv et al. 2014 Sample studied: 
Colon carcinoma 
Method: IHC for 
CXCR4 protein 
CXCR4 protein 
expression correlates with 
patient morbidity 
CXCR4 protein expression 
may be of utility as a 
prognosticator for poor 
outcome in patients with 
colon carcinoma. 
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associated with neoplasms of more aggressive phenotype (Basile 2008). In the 
same year, a study showed the presence of CXCR4 protein expression in head 
and neck squamous cell carcinoma and noted the absence of expression in 
adjacent normal tissue (Ou 2008). This study demonstrated a correlation 
between CXCR4 protein expression and tumor staging, supporting the predictive 
value of CXCR4 for poor patient outcome (Ou 2008).  
In a study of cells derived from malignant peripheral nerve sheath tumors 
(MPNST), researchers demonstrated that the CXCR4/CXCL12 axis promotes 
cell survival and metastasis (Mo 2013). Briefly, murine injection of CXCR4-
negative MPNST cells resulted in impaired in vivo tumor cell proliferation and 
attenuated tumorigenesis compared to injection with CXCR4-positive MPNST 
cells (Mo 2013). Interestingly, co-injection of the CXCR4 antagonist AMD3100 
and CXCR4-positive MPNST cells resulted in tumorigenesis similar to that of the 
CXCR4-negative MPNST cells (Mo et al., 2013). This same study demonstrated 
CXCR4 protein expression in human MPNSTs using immunohistochemistry (Mo 
2013). Based upon these findings Mo et al. hypothesized that the 
CXCR4/CXCL12 axis may be relevant in the progression of MPNST and may be 
of utility as a therapeutic target (Mo 2013). In 2006 Tucci et al. failed to 
demonstrate CXCR4 protein expression in Merkel cell carcinoma; however, a 
2012 study by Knapp et al. successfully demonstrated CXCR4 protein 
expression and noted statistically significant greater CXCR4 immunoreactivity in 
local nodal Merkel cell carcinoma metastasis biopsies compared to primary and 
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distant metastatic biopsies, leading the authors to conclude that CXCR4 is 
particularly crucial in the early stages of Merkel cell carcinoma progression (Tucci 
2006; Knapp 2012). These studies implicate the CXCR4/CXCL12 axis in the 
progression and metastasis of non-melanoma cutaneous malignancies and 
indicate CXCR4 as a potential prognosticator for poor outcome and target for 
therapy. 
Table 2. Chronologic historical overview of studies on CXCR4 in cutaneous non-melanoma 
malignancies 
REFERENCE STUDY DESIGN FINDINGS CONCLUSION 
Tucci et al. 
2006 
Sample studied: 
Merkel cell carcinoma 
Method: IHC for 
CXCR4 protein  
 
CXCR4 protein 
expression not detected. 
The CXCR4/CXCL12 
axis does not appear to 
be relevant in the 
etiopathogenesis of 
Merkel cell carcinoma. 
Basile et al. 
2008  
 
Samples studied: 
Actinic keratosis, basal 
cell carcinoma, 
cutaneous squamous 
cell carcinoma 
Method: IHC for 
CXCR4 protein  
 
Compared to normal 
skin, CXCR4 protein 
expression was 
downregulated in actinic 
keratosis and basal cell 
carcinoma, while 
expression was 
upregulated in 
cutaneous squamous 
cell carcinoma 
CXCR4 protein 
expression may be 
associated with 
cutaneous malignancies 
with potential for 
metastasis. 
Ou et al. 
2008 
Samples studied: 
squamous cell 
carcinoma (head and 
neck area) 
Method: IHC for 
CXCR4 protein 
CXCR4 protein 
expression correlates 
with clinical stage and 
presence of lymph node 
metastasis. 
CXCR4 protein 
expression may be of 
utility as a prognosticator 
for poor patient outcome 
in head and neck 
squamous cell 
carcinoma. 
Toyozowa et 
al. 2010 
Samples studied: 
dermatofibrosarcoma 
protuberance, 
malignant fibrous 
histiocytoma, 
dermatofibroma  
Method: IHC for 
CXCR4 protein 
CXCR4 protein 
expression higher in 
dermatofibrosarcoma 
and malignant fibrous 
histocytoma compared 
to dermatofibroma; 
CXCR4 protein 
expression higher in 
dematofibrosarcoma 
patients who relapsed 
patients  
CXCR4 protein 
expression may be of 
utility as a predictor of 
phenotypically aggressive 
cutaneous fibrohistocytic 
tumors. 
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Knapp et al. 
2012 
Samples studied: 
Merkel cell carcinoma, 
local nodal metastasis 
and distant metastasis  
Method: IHC for 
CXCR4 protein 
Higher expression in 
local nodal metastasis 
compared to primary 
and distant metastasis 
CXCR4 expression may 
be associated with the 
progression of Merkel cell 
carcinoma, particularly 
early stages of 
metastasis. 
Mo et al. 
2013 
Samples studied: 
malignant peripheral 
nerve sheath tumor 
(MPNST) cell lines 
and primary tumor 
Methods: In vivo 
murine injection of 
MPNST cells, RT-PCR 
for CXCL12 mRNA 
and IHC for CXCR4 
protein  
 
MPNST cells with 
CXCR4 knockdown 
displayed impaired in 
vivo tumor cell 
proliferation and 
attenuated 
tumorigenesis, as 
compared to injection 
with CXCR4 positive 
MPNST cells in murine 
models; CXCL12 highly 
expressed at sites of 
metastasis in murine 
models; administration 
of CXCR4 antagonist 
elicits abrogation of 
MPNST proliferation and 
metastasis in murine 
models; CXCR4 protein 
present in human 
MPNSTs  
The CXCR4/CXCL12 
axis may play a role in 
MPNST progression and 
metastasis. CXCR4 may 
be a putative target in 
treatment of MPNST. 
IHC=immunohistochemistry 
 
 
1.5.4 CXCR4/CXCL12 in melanoma  
The highly metastatic and variable behavior of melanoma has accentuated 
the need for early detection and targeted therapy. Expression of CXCR4 in 
melanoma was initially demonstrated in biopsies of primary cutaneous 
melanoma, melanoma metastatic to the lymph node and melanoma cell lines 
using multiple techniques that included immunohistochemistry and flow 
cytometry (Robledo 2001). In this study CXCR4 protein expression was noted in 
100% of biopsies of primary cutaneous melanoma as well as metastasis (n= 7 
and 5 respectively) and the melanoma cell lines MeWo, A375 and BLM, 
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indicating that the CXCR4/CXCL12 axis may be relevant in melanoma. This 
same study showed that CXCL12 greatly enhanced MeWo cell adhesion to the 
extracellular matrix protein fibronectin, facilitating the invasion of normal tissue by 
malignant cells (Robledo 2001). In 2001 Robledo et al. also showed that in vitro 
administration of CXCL12 induced phosphorylation of the MAP kinases p44/42 
and p38 (downstream of the Raf protein) indicating that CXCL12 could potentially 
be relevant in melanomagenesis (Robledo 2001). A year later Murakami et al. 
similarly demonstrated CXCR4 expression in 100% (n=3) of primary cutaneous 
melanoma biopsies and 40% (n=5) of pulmonary metastasis biopsies (Murakami 
2002). In the same study Murakami et al. transduced CXCR4 cDNA into B16 
melanoma cells and demonstrated that increasing CXCR4 protein expression 
resulted in significantly enhanced development of pulmonary metastasis in mice 
(Murakami 2002). Murakami et al. showed that administration of the CXCR4 
antagonists T22 inhibited the formation of metastasis, highlighting the potential 
therapeutic value of targeting the CXCR4/CXCL12 axis (Murakami 2002). This 
study also showed that in vitro administration of CXCL12 enhanced B16 
melanoma cell adhesion to pulmonary endothelial cells and promoted cell 
growth, identifying the CXCR4/CXCL12 axis is a potential contributor to 
melanomagenesis and the development of metastasis (Murakami 2002).  
Following the early findings of Robledo et al. and Murakami et al. were a 
number of studies demonstrating the prognostic utility of CXCR4 protein 
expression in primary cutaneous melanoma (Longo-Imedio 2005; Scala 2005;  
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Tucci 2007; Toyozawa 2012). Briefly, Longo-Imedio et al., demonstrated CXCR4 
protein expression in 35% (n=40) of primary cutaneous melanoma and showed 
that CXCR4 expression correlated with ulceration, increased tumor thickness, 
development of metastases, and patient morbidity (Longo-Imedio 2005). This 
same year Scala et al., correlated CXCR4 expression (56% positive, n=71) with 
shorter disease free survival and greater risk of morbidity in study patients with 
primary cutaneous melanoma (Scala 2005). Two years later Tucci et al. identified 
CXCR4 protein expression in 100% (n=30) of nodular melanoma biopsies and 
showed that expression correlated with greater Breslow depth and patient 
morbidity, supporting a role for the CXCR4/CXCL12 axis in melanoma growth 
and, the utility of CXCR4 as a prognosticator for poor patient outcome (Tucci 
2007). Most recently, Toyozawa et al. demonstrated CXCR4 protein expression 
in 100% (n=19) of primary cutaneous melanoma cases and noted an association 
between expression and tumor thickness >2 mm as well as the development of 
distant metastasis, delineating the contribution of the CXCR4/CXCL12 axis to 
melanoma progression and development of metastases (Toyozawa 2012). Of 
note, a 2012 study by Kühnelt-Leddihn et al. noted CXCR4 protein expression in 
82% (n=38) of primary cutaneous melanoma, but failed to demonstrate a 
correlation with established histopathologic prognosticators or patient morbidity 
(Kühnelt-Leddihn 2012). In addition to primary cutaneous melanoma, a 2012 
study highlighted the prognostic value of CXCR4 protein expression in uveal 
melanoma by correlating expression with the presence of liver metastasis 
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(Dobner 2012). 
 Higher expression of CXCR4 mRNA, like that of the protein, has also 
been identified as a prognosticator of poor outcome in melanoma in two studies 
(Franco 2010; Monteagudo 2012). In 2010 Franco et al. demonstrated high 
CXCR4 mRNA expression in 91% (n=23) of melanoma metastases to the lymph 
node and demonstrated an association between expression and shorter disease 
free survival (Franco 2010). Of note, this same study evaluated CXCR4 protein 
expression in all cases and observed a perfect overlap of mRNA and protein 
expressions (Franco 2010). More recently, Monteagudo et al. found that lower 
expression of CXCL12 mRNA compared to that of CXCR was a valuable 
prognosticator for the development of metastasis in primary cutaneous 
melanoma (Monteagudo 2012). The same study showed that CXCL12 mRNA 
expression, as compared to that of CXCR4 was four times greater in thin (≤1 
mm) than thick (>1 mm) primary cutaneous melanomas (Monteagudo 2012). Of 
note, a 2006 study by Kim et al. demonstrated CXCR4 mRNA expression in 89% 
(n=27) of melanoma biopsies, but noted the absence of a correlation with patient 
outcome (Kim 2006). 
The aforementioned studies highlight the relevance of the 
CXCR4/CXCL12 axis in the progression of melanoma as well as its prognostic 
value. The therapeutic value of targeting this chemokine axis has also been 
observed in a three studies (Scala 2006; Liang 2012; O’Boyle 2013). In 2006 
Scala et al. demonstrated abrogation of in vitro CXCL12 induced melanoma cell 
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proliferation by administering the CXCR4 antagonist AMD3100 (Scala 2006). In 
2012 Liang et al. administered the small molecule CXCR4 inhibitor MSX-122 and 
observed significant inhibition in uveal melanoma liver metastasis in mice, 
supporting that the previously observed in vitro effects of blocking the 
CXCR4/CXCL12 axis were maintained in an in vivo model (Liang 2012). A year 
later O’Boyle et al. compared the migratory response to CXCL12 of CHL-1 
melanoma cells transfected with either BRAFWT or BRAFV600E and found that 
migration was enhanced by BRAFV600E, but could be inhibited by the newly 
synthesized CXCR4 antagonist AMD11070, indicating that targeting of 
CXCR4/CXCL12 axis may be therapeutically relevant (O’Boyle 2013). Further 
highlighting the clinical relevance of the CXCR4/CXCL12 axis is a 2010 paper by 
Kim et al. which demonstrated that concomitant use of a CXCR4 antagonist and 
darcarbazine treatment on chemoresistant CD133+ melanoma cells effectively 
blocked tumor metastasis in mice (Kim 2010).  
Table 3. Chronologic historical overview of studies on CXCR4 in melanoma 
REFERENCE STUDY DESIGN FINDINGS CONCLUSION 
Robledo et al. 
2001 
Samples studied: 
Melanoma cell 
lines, primary 
cutaneous 
melanoma and 
metastasis 
Method: Flow 
cytometry for 
CXCR4 protein, 
IHC for CXCR4 
protein, in vitro cell 
adhesion assay 
and proliferation 
assay 
CXCR4 protein is present 
on melanoma cell lines 
and melanoma 
metastases; CXCL12 
induces enhanced 
fibronectin adhesion and 
phosphorylation of MAPK 
kinases. 
 
 
The CXCR4/CXCL12 axis 
may stimulate melanoma 
cell proliferation and 
invasion, contributing to 
melanoma progression and 
the development of 
metastases. 
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Murakami et 
al. 2002 
Samples studied: 
B16 melanoma cell 
line, primary 
cutaneous 
melanoma and 
pulmonary 
metastases 
Methods: Murine 
injection with 
CXCR4 positive 
and CXCR4 
negative 
melanoma cells 
and IHC for 
CXCR4 protein 
CXCR4 expression 
enhances pulmonary 
metastatic potential of 
melanoma cells in a 
murine model; CXCR4 is 
expressed on primary 
cutaneous melanoma 
and pulmonary 
metastasis 
The CXCR4/CXCL12 axis 
contributes to the 
metastatic capacity of 
melanoma cells in mice 
and expression is present 
in human melanoma. 
Longo-Imedio 
et al. 2005 
Sample studied: 
Primary cutaneous 
melanoma 
Method: IHC for 
CXCR4 protein 
CXCR4 protein 
expression correlates to 
the following: presence of 
ulceration, tumor 
thickness, development 
of lymph node 
metastasis, presence of 
distant metastasis, 
patient morbidity 
CXCR4 protein expression 
may be of utility as a 
prognosticator for poor 
patient outcome. 
Scala et al. 
2005 
Sample studied: 
Primary cutaneous 
melanoma with 
Breslow thickness 
>1 mm 
Method: IHC for 
CXCR4 protein 
CXCR4 protein 
expression correlates to 
presence of sentinel 
lymph node metastasis 
and patient morbidity 
CXCR4 protein expression 
may be of utility as a 
prognosticator for poor 
patient outcome. 
Scala et al. 
2006 
Sample studied: 
Melanoma cell 
lines and 
melanoma 
metastases 
Methods: RT-PCR 
for CXCR4 mRNA, 
in vitro proliferation 
assays and IHC for 
CXCR4 protein 
CXCR4 mRNA 
expressed in melanoma 
cell lines; CXCL12 
induces melanoma cell 
proliferation and these 
effects can be abrogated 
by AMD3100; CXCR4 
protein expressed in 
melanoma metastasis 
The CXCR4/CXCL12 axis 
may stimulate melanoma 
growth and metastasis. 
CXCR4 may be a putative 
target for therapeutic 
treatment. 
Kim et al. 
2006 
Sample studied: 
primary cutaneous 
melanoma 
Method: RT-PCR 
for CXCR4 mRNA 
No significant correlation 
observed between 
overexpression of 
CXCR4 protein and 
survival 
CXCR4 protein expression 
does not appear to have 
prognostic utility in primary 
cutaneous melanoma. 
Tucci et al. 
2007 
Sample studied: 
Primary cutaneous 
melanoma 
Method: IHC for 
CXCR4 protein 
CXCR4 protein 
expression correlates to 
Breslow thickness and 
patient morbidity 
CXCR4 protein expression 
may be of utility as a 
prognosticator for poor 
patient outcome.   
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Dobner et al. 
2009 
 
Sample studied: 
Primary uveal 
melanoma  
Methods: IHC for 
CXCR4 and 
CXCL12 protein  
CXCR4 protein 
expression substantially 
greater than CXCL12 
expression in primary 
tumor; correlation 
between CXCR4 
expression and 
development of hepatic 
metastasis 
The CXCR4/CXCL12 axis 
directs uveal melanoma 
cells to site of metastasis 
by a CXCL12 
concentration gradient. 
CXCR4 may have 
prognostic value. 
Franco et al. 
2010 
Sample studied: 
Primary cutaneous 
melanoma 
Methods: RT-PCR 
for CXCR4 mRNA 
and IHC for 
CXCR4 protein  
CXCR4 mRNA and 
protein expression 
correlate to patient 
morbidity 
CXCR4 protein expression 
may be of utility as a 
prognosticator for poor 
patient outcome.  
Kühnelt-
Leddihn et al. 
2012 
Sample studied: 
Primary cutaneous 
melanoma 
Method: IHC for 
CXCR4 
CXCR4 protein 
expression does not 
correlate with prognosis 
or survival. 
CXCR4 protein expression 
does not appear to have 
prognostic utility. 
Monteagudo 
et al. 2012 
Samples studied: 
Primary cutaneous 
melanoma and 
melanoma 
metastasis 
Methods: RT-PCR 
for CXCR4 and 
CXCL12 mRNA 
Low CXCL12/CXCR4 
ratio correlates with 
tumor thickness >1 mm 
and the development of 
metastasis 
The CXCR4/CXCL12 axis 
may contribute to 
melanoma progression and 
metastasis. 
CXCL12/CXCR4 mRNA 
ratio expression may be of 
utility as a prognosticator 
for poor patient outcome. 
Toyozawa et 
al. 2012 
Sample studied: 
Primary cutaneous 
melanoma  
Method: IHC for 
CXCR4 and 
CXCL12 protein 
CXCR4 protein 
expression correlates to 
the following: tumor 
thickness, development 
of distant metastasis, and 
CXCL12 protein 
expression. 
CXCR4 and CXCL12 
protein expressions may 
be of utility as 
prognosticators for poor 
patient outcome. 
O’Boyle et al. 
2013 
Samples studied: 
BRAFWT and 
BRAFV600E 
melanoma cell 
lines 
Method: In vitro 
migration assay 
Cell migration enhanced 
by BRAFV600E 
transfection and inhibited 
by the CXCR4 antagonist 
AMD11070 
CXCR4 may be a putative 
target for therapeutic 
treatment. 
IHC=immunohistochemistry 
 
 
1.6 Aims/Objectives  
As mentioned previously, one of the mechanisms by which the 
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CXCR4/CXCL12 axis has been shown to activate melanoma cell cycle 
progression is via stimulation of the MAPK pathway. While previous studies have 
delineated a role for the CXCR4/CXCL12 axis in melanoma metastasis and 
patient survival, the potential cooperativity with other known prognosticators has 
yet to be explored. Given this, in the current study, questions we sought answers 
to were the following: 
• Is there a correlation between CXCR4 and established histopathologic 
prognosticators and/or the mutational status of the MAPK BRAF protein in 
primary cutaneous melanoma? 
• Is there a correlation between CXCL12 and established histopathologic 
prognosticators and/or the mutational status of the MAPK BRAF protein in 
primary cutaneous melanoma? 
• Is there a correlation between CXCR4 and its ligand CCL12? 
• What is the correlation between CXCR4 expression by gene expression 
(mRNA RT-PCR) versus expression of the protein by 
immunohistochemistry? 
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MATERIALS AND METHODS 
 
2.1 Sample Selection 
This study was approved by the Boston University School of Medicine 
institutional review board (IRB # 478076). Formalin-fixed, paraffin-embedded 
tissues with a diagnosis of primary cutaneous melanoma (n=107) were retrieved 
from the archives of the Skin Pathology Laboratory, Boston University School of 
Medicine, Boston, MA, USA. Histopathologic sections of all cases were reviewed 
by two board-certified dermatopathologists (initial sign-out on all by a Board 
certified dermatopathologist; cases were then re-reviewed, and the diagnoses 
were confirmed by the senior author). All patient data were de-identified. 
Demographics of the patients included in the study are detailed in Table 4. 
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Table 4. Summary of patient demographics 
Age 67 years (mean), range 19-103 years 
Gender 
  Male 
  Female 
 
72 (67%) 
35 (33%) 
Site 
 Upper extremities 
 Lower extremities 
 Trunk 
 Head and Neck 
 
31 (29%) 
22 (21%) 
27 (25%) 
27 (25%) 
Thickness 
 <1mm 
 1-2mm 
 >2-4mm 
 >4mm 
1.75 mm (mean), range 0.2-10.4 mm 
44 (41%) 
30 (28%) 
21 (20%) 
12 (11%) 
Mitosis 
 Present 
 Absent 
 
69 (64%) 
38 (36%)  
Tumor Infiltrating 
Lymphocytes (TIL) 
  Present 
  Absent 
 
 
22 (21%) 
85 (79%) 
Ulceration 
 Present 
 Absent 
 
23 (21.5%) 
84 (78.5%) 
Regression 
 Present 
 Absent 
 
28 (26%) 
79 (74%) 
Vascular invasion (H&E) 
Present 
Absent 
 
2 (2%) 
105 (98%) 
AJCC Pathology Staging 
  T1a 
  T1b 
  T2a 
  T2b 
  T3a 
  T3b 
  T4a 
  T4b 
 
24 (22%) 
18 (17%) 
28 (26%) 
7 (6.5%) 
13 (12%) 
7 (6.5%) 
4 (4%) 
6 (6%) 
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2.2 DNA Analyses  
Five 10-um sections were cut from formalin-fixed, paraffin-embedded 
archival tissue blocks using a micrometer and placed in eppendorf tubes. For 
deparaffinization samples were incubated at 60°C in 750 µl xylene for 5 minutes, 
centrifuged at 14000 rotations per minute for 2 minutes, the supernatant was 
discarded, incubated at 60°C in 750 µl ethanol for 5 minutes, centrifuged at 
14000 rotations per minute for 2 minutes and the supernatant was discarded. For 
separation of DNA and RNA from this mixture samples were resuspended in a 
mixture of 150 µl Buffer PKD (Qiagen, Valencia, CA, USA) and 10 µl proteinase 
K, incubated at 56°C for 15 minutes, placed on ice for 3 minutes, and centrifuged 
at 14000 rotations per minute for 15 minutes. The RNA containing supernatant 
was removed for PCR analysis (see section 2.3 RNA Analyses). Depending on 
sample size 15-25 µl Proteinase K were added to the remaining pellet and 
digested at 55°C overnight. The crude DNA containing pellet was boiled for 10 
minutes, quantified by spectrophotometer (Table 2) and diluted to the appropriate 
concentration (100 ng/µl).  
For determination of BRAF mutational status 1-2 µl sample DNA war 
amplified in a volume of 12.5 µl containing 200 µM dNTP, 100-200 nM of 
primers, 1.5-2.0 mM MgCl2, 10 mM Tris HCL (pH 8.3), 50 mM KCL and 0.25 µl of 
TaqGold polymerase (Applied Biosystems, CA, USA). Cycling was carried out in 
a GeneAmp PCR system 9700 thermal cycler (Applied Biosystems, CA USA) as 
follows: 5 minutes at 94°C; 45 cycles of 94°C for 30 seconds, 55°C for 30 
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seconds, 72°C for 30 seconds with a final extension step of 5 minutes at 72°C. 
PCR products were visualized on a 2-3% agarose gel. Sanger sequencing was 
performed on BRAF gene exon 15 with forward primer BRAF_X15F 5'-
TGCTCTGATAGGAAAATGAGATC-3' and reverse primer BRAF_X15R 5'-
CTAGTAACTCAGCAGCATCTCAG-3' and analyzed by the Genetic Analyzer 
3130XL. The sequencing results were analyzed with ABI DNA Sequencing 
Analysis Software version 6. Appropriate positive, negative and no-DNA controls 
were included in each batch of PCR and sequencing reactions. 
 
2.3 RNA Analyses 
Deparaffinization and a simple proteinase K digestion were performed as 
described in section 2.2 DNA Analyses. RNA extraction was carried out per the 
AllPrep DNA/RNA Mini Kit (Qiagen). Briefly, the RNA containing supernatant 
obtained from 2.2 DNA Analyses and was incubated at 80°C for 15 minutes, 
centrifuged at 14,000 rotations per minute, and mixed with 320 µl Buffer RLT and 
1120 µl ethanol. Samples were centrifuged through an RNeasy MinElute spin 
column at 10,000 rotations per minute, the flow-through was discarded and these 
steps were repeated with 350 µl Buffer FRN. 80 µl DNase I incubation mix (10 µl 
DNase I and 70 µl Buffer RDD) were added to the RNeasy column membrane 
and after 15 minutes 500 µl Buffer FRN were added to each column. Each 
MinElute spin column was centrifuged at 10,000 rotations per minute for 15 
seconds and placed in a new 2 ml collection tube for a second centrifugation. 
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Buffer RPE was added and centrifuged through twice in 500 µl aliquots and the 
RNeasy MinElute spin column was placed in a new 1.5 mL collection tube. 25 µl 
RNase-free water were added to the spin column membrane and incubated for 1 
minute at room temperature before being centrifuged at full speed for 1 minute. A 
nanodrop was used to quantify RNA content in each sample (Table 3). 
Based upon total highest RNA content 96 samples were selected for 
cDNA synthesis and RT-PCR analysis. The RevertAid First Strand cDNA 
Synthesis Kit (Thermo Scientific, Waltham, Massachusetts, USA) was used for 
converting RNA to cDNA. Briefly, approximately 2 µg RNA were added to a 
nuclease-free tube along with 1 µl random hexamer primer and the appropriate 
volume of nuclease-free water to bring the total volume to 12 µl. Added to this 
solution were 4 µl 5X Reaction Buffer, 1 µl RiboLock RNase Inhibitor, 2 µl 10 mM 
dNTP Mix, and 1 µl RevertAid M-MuLV Reverse Transcriptase. Samples were 
incubated as follows: 5 minutes at 25°C, 60 minutes at 42°C, and 5 minutes at 
70°C.  
Real time-PCR was performed using the ABI 7900HT Fast Real-Time 
PCR instrument. Levels of CXCR4 mRNA were assessed in reference to the 
internal positive control beta actin. Each sample was run in duplicates for both 
CXCR4 (Qiagen) and beta actin (Qiagen). All samples were analyzed in the RT2 
SYBR Green ROX qPCR Mastermix (Qiagen). In order to normalize CXCR4 
mRNA expression across each sample a ∆Ct was calculated by using the 
equation CtCXCR4-Ctbeta actin. Briefly, higher ∆Ct values are indicative of lower 
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mRNA expression. 
 
2.4 Immunohistochemistry  
Immunohistochemistry was performed on 4 µm formalin-fixed, paraffin-
embedded sections using commercially available rabbit polyclonal antibodies 
anti-CXCR4 (ab2074 Abcam, Cambridge, MA, USA) and anti-SDF-1 alpha (anti-
CXCL12) (ab9797 Abcam, Cambridge, MA, USA) at a dilution of 1:500. Target 
retrieval using low pH Target Retrieval solution (DAKO, Carpinteria, CA, USA) 
was performed at 97°C for 20 min. The slides were treated with dual endogenous 
enzyme block (DAKO) before primary antibody staining and overnight incubation 
at 4°C. The remaining steps were carried out using the DAKO Autostainer Plus 
(DAKO). Color development and contrast were achieved using DAB and 
hematoxylin, respectively. For all immunohistochemical stains used in the study 
appropriate positive and negative controls were included with each run. All 
stained slides were reviewed and scored by the first author (BM) and the senior 
author (MM) in a blinded fashion with respect to each other’s scores. Any 
disagreements were reviewed together to achieve a consensus score.  
For CXCR4, cytoplasmic staining of suprabasal keratinocytes, membrane 
staining of eccrine glands, and cytoplasmic staining of lymphocytes served as the 
positive internal controls in each case where they could be visualized. A normal 
spleen sample was used as a positive control for each staining batch. For 
CXCL12, cytoplasmic staining of suprabasal keratinocytes in the epidermis, 
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cytoplasmic staining of endothelial cells and cytoplasmic staining of mature 
sebocytes were used as internal positive controls for CXCL12 in each case 
where they could be visualized. A rectal carcinoma sample was used as a 
positive control for each staining batch. 
For both stains, a semi-quantitative scoring system was utilized with the 
following cut-offs: 0=<1%, 1=1-10%, 2=>10-50% and 3=>50%. Cells were 
considered positive when the intensity of staining was equal to or greater than 
staining of the internal positive controls. For purposes of statistical analyses 
cases with >10% or a score of 2 or more were considered positive. 
 
2.5 Statistical analyses 
Univariate analysis of CXCR4 at the protein level (immunohistochemical 
staining) and RNA level (RT-PCR) was used to inform variable selection for 
multivariable analysis and to identify potential confounders. Significant 
differences among subgroups for each clinical factor were examined using a 
difference of proportions for protein expression and t-test for difference of mean 
RNA expression. Differences in RNA expression among AJCC stages were 
analyzed using a Welch adjustment to ANOVA with stage 2 as the reference.  
Clinical factors that showed a significant difference in the presence of 
CXCR4 on either the protein or RNA level were then analyzed by multivariable 
logistic regression to assess for the association with prognosticators. Depth of 
the tumor was fully captured by AJCC stage 1 and dropped from the 
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multivariable model. 
Adjusting for multiple comparisons in the analyses of both protein and 
RNA expression did not alter covariate selection for logistic regression at the 
0.20 level for BRAF, AJCC staging, mitosis, host response, ulceration, or 
regression. Both Hochberg, and the more conservative Bonferroni method, were 
used to adjust p-values for the 14 immunohistochemical and 7 mRNA expression 
analyses. The results were comparable, except for stage 2 AJCC and 
Regression variables, for which Hochberg but not Bonferroni were <0.20. 
Therefore to reduce the probability of a type II error, we relied on Hochberg’s 
method to adjust p-values and guide multivariable selection. 
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RESULTS 
 
3.1 DNA extraction and BRAF status  
 DNA extraction and determination of BRAF mutation status were 
successful in all 107 samples analyzed. A BRAF mutation was observed in 
26/107 (24.3%) of cases. These included mutations in BRAFV600E (n=18; cases 
K3, K5, K9, K10, K11, K16, K36, K44, K45, K57, K60, K65, K68, K71, K73, K80, 
K87 and K89), L597S (n=2; cases K6 and K67), S607F (n=1; case K13), K601E 
(n=1; case K85), V600K (n=3; cases K51, 79 and K81), and V600R (n=1; case 
93) (Table 5 and Figure 2). 
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Table 5. DNA extraction and BRAF status 
Case DNA (ng/µl) 
BRAF 
Status Case 
DNA 
(ng/µl) 
BRAF 
Status Case 
DNA 
(ng/µl) 
BRAF 
Status 
K1 165 WT K38 170 WT K74 1355 WT 
K2 1640 WT K39 435 WT K75 595 WT 
K3 2030 V600E K40 305 WT K76 865 WT 
K4 540 WT K41 210 WT K77 255 WT 
K5 1376 V600E K42 950 WT K78 500 WT 
K6 12100 L597S K43 320 WT K79 480 V600K 
K7 285 WT K44 1620 V600E K80 1155 V600E 
K8 155 WT K45 475 V600E K81 1455 V600K 
K9 210 V600E K46 150 WT K82 2575 WT 
K10 124 V600E K47 325 WT K83 1190 WT 
K11 355 V600E K48 230 WT K84 310 WT 
K12 195 WT K49 500 WT K85 1125 K601E 
K13 380 S607F K50 590 WT K86 135 WT 
K14 855 WT K51 185 V600K K87 180 V600E 
K15 125 WT K52 630 WT K88 270 WT 
K16 205 V600E K53 1190 WT K89 955 V600E 
K17 1565 WT K54 1325 WT K90 335 WT 
K18 330 WT K55 2950 WT K91 850 WT 
K19 340 WT K56 655 WT K92 1110 WT 
K20 425 WT K57 1575 V600E K93 750 V600R 
K21 2550 WT K58 365 WT K94 670 WT 
K23 625 WT K59 410 WT K95 400 WT 
K24 370 WT K60 225 V600E K96 320 WT 
K25 3430 WT K61 165 WT K97 195 WT 
K26 120 WT K62 120 WT K98 290 WT 
K27 190 WT K63 290 WT K99 315 WT 
K28 160 WT K64 80 WT K100 445 WT 
K29 60 WT K65 80 V600E K101 330 WT 
K30 100 WT K66 130 WT K102 115 WT 
K31 575 WT K67 165 L597S K103 170 WT 
K32 110 WT K68 180 V600E M40 180 WT 
K33 230 WT K69 1245 WT M41 275 WT 
K34 200 WT K70 690 WT M42 165 WT 
K35 275 WT K71 645 V600E M43 240 WT 
K36 390 V600E K72 1295 WT M44 3470 WT 
K37 230 WT K73 780 V600E    
DNA concentrations determined by spectrophotometry. BRAF status determined by DNA Sanger 
sequencing. Blue=BRAF wild type. Green=BRAF mutant. 
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Figure 2: DNA Sanger sequencing  
  
 
Clockwise from top left: BRAFV600E; BRAFV600K; BRAFV600R; BRAFV601E. 
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3.2 RNA extraction and CXCR4 mRNA expression via RT-PCR  
 RNA extraction was performed on 100 samples and RT-PCR for CXCR 
was performed on the 96 samples yielding the highest RNA content. Of these, 89 
samples were successfully analyzed for CXCR4 mRNA content. The mean ∆Ct 
value for the 89 samples successfully analyzed was 6.37 ± 1.68 (Table 6). 
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Table 6. RNA extraction and ∆Ct values (CXCR4 mRNA) 
Case RNA (ng/µl) 
∆Ct 
(mean) Case 
RNA 
(ng/µl) 
∆Ct 
(mean) Case 
RNA 
(ng/µl) 
∆Ct 
(mean) 
K1 75 9.54 K38 43 2.29 K74 794 5.99 
K2 1337 4.53 K39 179 6.50 K75 414 6.82 
K3 1850 5.37 K40 105 6.31 K76 90 5.73 
K4 115 5.32 K41 30 7.20 K77 316 8.84 
K5 955 N/A K42 197 5.17 K78 567 8.36 
K6 75 N/A K43 108 N/A K79 449 6.37 
K7 27 5.28 K44 186 3.28 K80 305 5.48 
K8 40 6.13 K45 70 6.48 K81 824 5.09 
K9 165 5.00 K46 7 N/A K82 588 N/A 
K10 863 5.85 K47 133 6.44 K83 647 5.51 
K11 168 5.42 K48 241 7.48 K84 162 5.17 
K12 239 5.46 K49 116 5.72 K85 458 5.63 
K13 142 5.63 K50 198 9.91 K86 119 8.21 
K14 269 5.86 K51 33 5.57 K87 277 4.59 
K15 16 N/A K52 384 7.46 K88 128 6.11 
K16 27 5.13 K53 1147 7.62 K89 644 5.64 
K17 331 5.16 K54 986 N/A K90 76 9.76 
K18 127 6.17 K55 270 4.55 K91 149 8.03 
K19 35 6.62 K56 600 4.06 K92 348 8.87 
K20 106 5.96 K57 1347 N/A K93 467 7.92 
K21 383 5.38 K58 72 6.65 K94 124 8.83 
K23 72 7.65 K59 584 N/A K95 241 6.72 
K24 127 6.08 K60 74 5.49 K96 58 6.62 
K25 1860 6.48 K61 91 6.55 K97 49 9.82 
K26 93 9.04 K62 30 5.64 K98 103 7.43 
K27 147 3.91 K63 101 2.90 K99 46 7.79 
K28 73 5.98 K64 75 5.46 K100 371 8.10 
K29 18 N/A K65 76 9.86 K101 82 8.14 
K30 40 5.75 K66 34 10.69 K102 N/A N/A 
K31 390 6.26 K67 17 N/A K103 N/A N/A 
K32 35 7.51 K68 143 7.44 M40 N/A N/A 
K33 67 N/A K69 969 N/A M41 N/A N/A 
K34 390 6.75 K70 528 7.26 M42 N/A N/A 
K35 286 5.14 K71 565 3.82 M43 N/A N/A 
K36 165 4.09 K72 501 7.14 M44 N/A N/A 
K37 114 3.20 K73 146 6.11    
RNA concentrations determined by nanodrop spectrophotometry. Higher ∆Ct values are 
indicative of lower CXCR4 mRNA expression. 
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3.3 CXCR4 mRNA expression correlates with select histopathologic 
prognosticators and BRAF mutational in primary cutaneous melanoma.  
Expression of CXCR4 mRNA (mean ∆Ct values) was significantly different 
among those exhibiting a host response (present=6.63, absent=5.39, p=0.0003) 
(Figure 3) and BRAF mutation (mutant=5.69, wild-type=6.60, p=0.03).  
Expression of CXCR4 mRNA was also significantly different among the AJCC 
stages (T1=6.13, T2=7.28, T3=5.94, T4=5.87, p=0.01) (Table 7). 
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Figure 3. Representative examples of cases from study 
 
 
A-C=Melanoma with absent host response and low CXCR4 mRNA expression (∆Ct=9.04). D-
F=Melanoma with brisk host response and high CXCR4 mRNA expression (∆Ct=5.00). 
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3.4 Immunohistochemical analyses of CXCR4 and CXCL12 protein 
expressions 
Overall, positive staining for CXCR4 was noted in 59/100 (59%) (7 failed) 
cases with the following scores: 0=12/100 (12%), 1=29/100 (29%), 2=30/100 
(30%), and 3=29/100 (29%). Positive staining for CXCL12 was noted in 35/103 
(34%) (4 failed) cases with the following scores: 0=47/103 (46%), 1=21/103 
(20%), 2=22/103 (21%), and 3=13/103 (12%) (Table 7, Figure 4). 
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Table 7. Immunohistochemical staining for CXCR4 and CXCL12 
Case CXCR4 CXCL12 Case CXCR4 CXCL12 Case CXCR4 CXCL12 
K1 + + K38 - - K74 + - 
K2 - - K39 + + K75 - - 
K3 - + K40 - - K76 - - 
K4 + - K41 - - K77 + - 
K5 + + K42 + - K78 - - 
K6 + + K43 - + K79 - + 
K7 + + K44 + - K80 - - 
K8 + - K45 + - K81 + - 
K9 + - K46 + + K82 - - 
K10 + + K47 + - K83 - - 
K11 + - K48 - - K84 + - 
K12 + - K49 + - K85 - - 
K13 - - K50 - - K86 + - 
K14 + + K51 - + K87 - - 
K15 N/A N/A K52 - + K88 - - 
K16 + - K53 - - K89 - - 
K17 - - K54 + - K90 - + 
K18 N/A N/A K55 + + K91 + + 
K19 N/A N/A K56 + + K92 + - 
K20 + + K57 - - K93 + - 
K21 + + K58 - + K94 + - 
K23 - + K59 - - K95 - - 
K24 N/A N/A K60 + - K96 + - 
K25 - + K61 + + K97 + + 
K26 + + K62 N/A - K98 - - 
K27 + - K63 N/A - K99 + + 
K28 + - K64 - - K100 + - 
K29 + + K65 + - K101 + - 
K30 + - K66 N/A - K102 + - 
K31 + - K67 + - K103 - - 
K32 + - K68 + + M40 + - 
K33 + - K69 - + M41 + - 
K34 - - K70 - + M42 + - 
K35 + + K71 + - M43 + - 
K36 - + K72 - - M44 - + 
K37 + + K73 - +    
Blue=CXCR4+/CXCL12+. Green=CXCR4-/CXCL12-. Orange=CXCR4+/CXCL12-. Red=CXCR4-
/CXCL12+. N/A=not scored due to absence of lesional area in tissue studied. 
 
  
 Figure 4: Immunohistochemical s
A-C=Case 23; A=H&E, 4x, 
D-F=Case 94; D=H&E, 4x, E
H=CXC12 4x (score 3), I=CXCL12 20x
 
 
3.5 CXCR4 protein expression correlates with select histopathologic 
prognosticators and BRAF mutation in primary cutaneous melanoma. 
In a univariate analysis, compared with CXCR4 negative samples, the 
proportion of CXCR4 positive samples was significantly gre
with absence of the following: mitotic figures (
regression (p=0.02), vascular invasion (
(p=0.02). A trend towards statistical significance was noted in melanomas with 
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taining for CXCR4 and CXCL12 
B=CXCR4 20x (score 0), C=eccrine glands (positive internal control). 
=CXCR4 4x (score 3), F=CXCR4 20x. G-I=Case 90; 
. 
ater in melanomas 
p=<0.0001), ulceration (
p=0.01), and the BRAF mutation 
 
G=H&E, 4x, 
 
p=0.0008), 
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absence of CXCL12 expression (p=0.05). Among samples from patients 
presenting at shallower AJCC stages (1-2), we found a significantly larger 
CXCR4 positive proportion compared to patients presenting at deeper stages (3-
4) (Table 8, Figure 4).  
In a multivariable logistic regression analyses, compared to stage 1, stage 
3 (OR=0.16, 95%CI: 0.04–0.68, p=0.013) and stage 4 (OR=0.21, 95%CI: 0.03–
0.92, p=0.040) were significantly associated with lower odds of staining CXCR4 
positive. Mitotic figures were also significantly associated with lower odds of 
staining CXCR4 positive (OR=0.21, 95%CI: 0.06–0.73, p=0.14). Although not 
significant, BRAF mutation (OR=2.31, 95%CI: 0.67–8.01) and host response 
(OR=2.84, 95%CI: 0.72–11.20) are suggestive of an association (Table 9). 
Vascular invasion was not analyzed due to the limited number of samples (n=2). 
 
3.6 CXCL12 protein expression does not correlate with select 
histopathologic prognosticators and BRAF mutation in primary cutaneous 
melanoma 
No association was observed between CXCL12, histopathologic 
prognosticators, and BRAF mutation in primary cutaneous melanoma (Table 9). 
CXCL12 was not globally associated with the clinical values as demonstrated in 
a separate logistic model (Χ2=8.61, df=8, p=0.376). 
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Table 8. Univariate analyses of CXCR4 protein and mRNA expression 
 
* Marginal significance, ** Significant, *** Highly significant,   Welch’s adjustment for unequal 
variance (ANOVA), § Not calculated due to only one sample of vascular invasion,  Kappa 
Agreement between CXCR4 and CXCL12: K=0.1133, p=0.8814 
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Table 9. Multivariate analyses of CXCR4 and CXCL12 protein expression profiles 
 
 
 
 
3.7 CXCR4 protein expression does not correlate with expression of CXCR4 
mRNA 
The mean ∆Ct value for cases that were positive for expression of the 
CXCR4 protein was 6.38 ± 1.72 and the mean ∆Ct for negative cases was 6.36 ± 
1.49 (p=0.96). Linear correlation analysis of ∆Ct (mRNA) and 
immunohistochemistry (protein) showed a low correlation coefficient (r=0.1).  
  
CXCR4 CXCL12
Clinical Factor
(n=100) OR 95%CI p-value Signifigance OR 95%CI p-value Signifigance
BRAF mutant 2.31 0.67 – 8.01 0.1871 0.99 0.33 – 2.91 0.9883
AJCC
Ref = Stage 1 --- --- --- --- --- ---
Stage 2 0.99 0.29 – 3.39 0.9828 0.41 0.13 – 1.25 0.1169
Stage 3 0.16 0.04 – 0.68 0.0127 ** 0.15 0.03 – 0.69 0.0149
Stage 4 0.17 0.03 – 0.92 0.0398 * 0.6 0.13 – 2.83 0.5165
Mitotic Figures 0.21 0.06 – 0.73 0.0141 ** 1.49 0.54 – 4.15 0.4439
Host Response 2.84 0.72 – 11.20 0.1358 0.54 0.16 – 1.88 0.335
Ulceration 0.7 0.22 – 2.29 0.5571 1.57 0.48 – 5.12 0.4577
Regression 0.4 0.13 – 1.28 0.1234 0.93 0.34 – 2.56 0.8863
 61
DISCUSSION 
 
 Expression of CXCR4 mRNA in melanoma was initially reported in 
melanoma metastases in 2004 (Kim 2004). Since then, studies ascertaining the 
utility of CXCR4 mRNA as a prognosticator in primary cutaneous melanoma 
have revealed conflicting results. While Kim et al., on a study of 23 patients, 
found that low versus high CXCR4 expression had no correlation with patient 
survival, Franco et al., on a study of 47 patients, showed that expression in 
melanoma lymph node metastases correlated to shorter disease free survival 
and Monteagudo et al., on a study of 51 patients, demonstrated the 
prognosticative value of the CXCL12/CXCR4 mRNA ratio by showing that a low 
ratio correlated to tumor thickness >1 mm and the development of metastases 
(Kim 2004; Franco 2010; Monteagudo 2012). Findings from the current study, the 
largest to date studying primary cutaneous melanomas, favor a role for CXCR4 
mRNA expression as a prognosticator associated with poor clinical outcome as 
we found higher CXCR4 mRNA expression in tumors in AJCC stages 3 and 4 
compared to stage 2.  
Of note, we found significant differences in primary cutaneous melanomas 
with and without a host response with reduced CXCR4 mRNA expression in the 
former. An established cell non-autonomous tumor suppressive effect that has 
proven to be crucial for the development and progression of many different types 
of human cancers is the host immune response (Zitvogel 2006). It has been 
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previously shown that tumor cells develop strategies to escape immune 
surveillance (Mapara & Sykes 2004). However, tumors vary in their ability to 
evade the host immune response, which in some instances might explain their 
differential response to immune-based therapies. With the aim of identifying the 
genetic determinant of immune response in primary cutaneous melanoma, we 
have recently shown that the tumor suppressor, phosphatase and tensin 
homologue (PTEN), is an important regulator of the host immune response 
against melanoma cells (Dong 2013). Findings from the current study indicate 
that, like PTEN, CXCR4 may be of utility as a biomarker for recruiting melanoma 
patients for immunotherapy. 
While the treatment of malignant melanoma with inhibitors targeting the 
BRAFV600E mutation has demonstrated dramatic clinical response with 
improved progression free and overall survival in the majority of melanoma 
patients receiving treatment, failed therapies are noted 6-8 months after initiation 
in approximately 47% patients (Filitis & Mahalingam 2013). The potential 
cooperativity between the mutational status of BRAF and the CXCR4/CXCL12 
axis has been shown in a recent study (O’Boyle 2013). In comparing the 
migratory response of melanoma cells transfected with BRAFWT or BRAFV600E 
to CXCL12, O’Boyle et al. found that migration appeared to be enhanced by 
BRAFV600E transfection and inhibited by the CXCR4 antagonist AMD11070 
(O’Boyle 2013). Given this, our findings of higher CXCR4 mRNA expression in 
patients with a BRAF mutation lends credence to the hypothesis that CXCR4 
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may be an ancillary molecule to explore as a putative target in primary cutaneous 
melanoma.  
The samples we worked with were archival formalin-fixed paraffin-
embedded tissue samples. Evers et al. showed that paraffin embedding of tissue 
samples can cause RNA aggregation and reductions in yield and quality (Evers 
2011). As a result of the effects of paraffin embedding Evers et al. observed 10- 
to 160-fold decreases in amplifiable RNA compared to controls (Evers 2011). In 
addition to during paraffin embedding, Nolan et al. demonstrated that extracted 
RNA can be rendered unstable by the environment and storage time should be 
limited to prevent breakdown (Nolan 2006). As has been demonstrated 
previously, studies measuring target mRNA expression via RT-PCR are reliant 
upon high RNA yield as well as superior quality from tissue samples (Fleige & 
Pfaffl 2006). Perez-Novo et al. showed that RNA instability or low RNA 
concentrations can significantly alter RT-PCR measurements (Pérez-Novo 
2005). In our study, to conserve RNA stability all extracted RNA samples were 
stored at -120°C and cDNA conversion and RT-PCR were performed within two 
weeks of extraction. To ensure proper RNA concentrations Nanodrop 
spectrophotometry was performed on all samples and those demonstrating the 
highest RNA concentration were selected for RT-PCR analysis.  
 Studies demonstrating the utility of CXCR4 protein as a prognosticator in 
primary cutaneous melanoma, like that of CXCR4 mRNA, have been limited by 
sample size and show no consensus. Favoring a role for CXCR4 protein as a 
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prognosticator are studies by Longo-Imedio et al., on 40 patients with primary 
cutaneous melanoma, showing that CXCR4 expression correlates with 
ulceration, increased tumor thickness, development of metastases, and patient 
morbidity; by Tucci et al., on 30 patients with nodular melanoma, demonstrating 
an association between CXCR4 protein expression and greater Breslow depth of 
the primary tumor as well as patient morbidity; and by Toyozawa et al., on 19 
patients with primary cutaneous melanoma, noting an association between 
CXCR4 protein expression and tumor thickness >2 mm as well as the 
development of distant metastases (Longo-Imedio 2005; Tucci 2007; Toyozawa 
2012). Studies refuting an association to established histopathologic 
prognosticators are limited to two: one by Scala et al. on 71 patients with primary 
cutaneous melanoma and another by Kühnelt-Leddihn et al. on 38 patients 
(Scala 2005; Kühnelt-Leddihn 2012). Our findings support the fact that CXCR4 
protein expression is not an adverse prognosticator by demonstrating in a 
multivariable logistic regression analysis that stages 3 and 4, compared to stage 
1, were significantly associated with lower odds of staining CXCR4 positive. Also, 
mitoses were significantly associated with lower odds of staining CXCR4 
positive.  
 In an effort to accurately demonstrate CXCR4 and CXCL12 protein 
expression we performed optimization of the immunohistochemistry protocol to 
ensure maximal target protein staining with minimal background. Control 
samples were stained with primary antibody at a range of dilutions (1:100, 1:250, 
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1:500, 1:1000) and incubated at room temperature or 4°C for varying lengths of 
time (2-12 hours). A common challenge to overcome when performing 
immunohistochemistry on formalin-fixed paraffin embedded samples is the 
presence of protein cross-linking, which can mask target proteins from being 
recognized by their corresponding antibody (Shi 1991). One way of overcoming 
this is using heat-induced antigen retrieval, which causes protein unfolding 
allowing for efficient recognition by the antibody (Shi 1991). Our study performed 
heat-induced antigen retrieval in low pH for 20 minutes at 97°C. During 
immunohistochemical optimization, we manipulated antigen retrieval temperature 
and incubation time to ascertain ideal staining. These steps allowed for accurate 
staining and efficient quantification of protein expression within lesional tissue. 
 In the only other study to evaluate an association between CXCR4 mRNA 
and protein expression in melanoma, unlike us, Franco et al. noted a perfect 
overlap of semi-quantitative mRNA and protein measurements (Franco 2010). 
Possible differences may relate to antibody used (polyclonal versus monoclonal) 
and cut-off for interpreting positivity (10 versus 30%). Of note, several previous 
studies have shown that non-transcriptional variance may be attributed to 
translation and/or protein degradation (Preiss 1998; Gebauer & Hentze 2004; 
Abreu 2009). For example, Abreu et al. noted that because transcription and 
translation do not occur simultaneously, there is greater opportunity for transcript 
modification and breakdown while Gebauer and Hentze showed that post 
transcriptional modification, particularly phosphorylation, can greatly impact 
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translational rate and efficiency (Gebauer & Hentze 2004). In addition to changes 
in translation, protein degradation in the form of lysosomal degradation and 
ubiquitin-mediated proteolysis has also been shown to contribute to variance in 
mRNA and protein expressions (Abreu 2009).  
 One previous study, on 19 patients, has shown that there appears to be a 
significant and positive correlation between immunohistochemical expression of 
CXCR4 and CXCL12 with 57% (4 of 7 cases) demonstrating “high” expression of 
both (Toyozawa 2012).  Of the 59 cases that were CXCR4 positive, we noted 
CXCL12 positivity in only 21 (36%) and no statistically significant correlation 
between the two. The larger number of cases in the current study argues in favor 
of lack of an association between CXCR4 and CXCL12. 
 In conclusion, preliminary findings from the current study, the largest to 
date on primary cutaneous melanoma, suggest that CXCR4 may have multiple 
clinical uses. These include its potential utility as a prognosticator, given that 
expression of the protein is less frequently observed in melanomas with mitoses 
and depth >2 mm, its potential utility as a biomarker for recruiting melanoma 
patients for immunotherapy given the association between CXCR4 mRNA 
expression and a brisk host response and, its utility as a putative therapeutic 
target given our findings of higher CXCR4 mRNA expression in patients with a 
BRAF mutation. Longitudinal studies are required to confirm our findings.  
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